{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:33:55Z","timestamp":1793230435327,"version":"4.5.0"},"reference-count":764,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored. Compared with conventional treatments, small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing. As a result of recent technological advances, efficient small nucleic acid delivery for therapeutic and biomedical applications has been achieved, accelerating their clinical translation. Here, we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms. We also discuss the key advances in the design, development and therapeutic application of each delivery platform. Furthermore, this review presents comprehensive profiles of currently approved small nucleic acid drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers and 6 siRNA drugs, summarizing their modifications, disease-specific mechanisms of action and delivery strategies. Other candidates whose clinical trial status has been recorded and updated are also discussed. We also consider strategic issues such as important safety considerations, novel vectors and hurdles for translating academic breakthroughs to the clinic. Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously \u201cundruggable\u201d targets, suggesting that they could be useful for guiding the development of additional clinical candidates.<\/jats:p>","DOI":"10.1038\/s41392-024-02112-8","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T20:02:03Z","timestamp":1741550523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":171,"title":["Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines"],"prefix":"10.1038","volume":"10","author":[{"given":"Mohan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9989-0394","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2112_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","volume":"403","author":"A Schambach","year":"2024","unstructured":"Schambach, A. et al. A new age of precision gene therapy. Lancet 403, 568\u2013582 (2024).","journal-title":"Lancet"},{"key":"2112_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X. H. Antisense technology: an overview and prospectus. Nat. Rev. Drug Discov. 20, 427\u2013453 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108130","volume":"65","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnol. Adv. 65, 108130 (2023).","journal-title":"Biotechnol. Adv."},{"key":"2112_CR4","doi-asserted-by":"publisher","first-page":"20230165","DOI":"10.1002\/EXP.20230165","volume":"4","author":"L Xu","year":"2024","unstructured":"Xu, L. et al. Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery. Exploration 4, 20230165 (2024).","journal-title":"Exploration"},{"key":"2112_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. & Wood, M. J. A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","volume":"352","author":"T Ramasamy","year":"2022","unstructured":"Ramasamy, T. et al. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. J. Control Release 352, 861\u2013878 (2022).","journal-title":"J. Control Release"},{"key":"2112_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson, M. L. & Zamecnik, P. C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 75, 285\u2013288, (1978).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett, C. F. Therapeutic Antisense Oligonucleotides Are Coming of Age. Annu Rev. Med. 70, 307\u2013321 (2019).","journal-title":"Annu Rev. Med."},{"key":"2112_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tig.2008.03.007","volume":"24","author":"JS Whangbo","year":"2008","unstructured":"Whangbo, J. S. & Hunter, C. P. Environmental RNA interference. Trends Genet 24, 297\u2013305 (2008).","journal-title":"Trends Genet"},{"key":"2112_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal, N. et al. RNA interference: biology, mechanism, and applications. Microbiol Mol. Biol. Rev. 67, 657\u2013685 (2003).","journal-title":"Microbiol Mol. Biol. Rev."},{"key":"2112_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bmj.328.7450.1245","volume":"328","author":"J Downward","year":"2004","unstructured":"Downward, J. RNA interference. Bmj 328, 1245\u20131248 (2004).","journal-title":"Bmj"},{"key":"2112_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494\u2013498 (2001).","journal-title":"Nature"},{"key":"2112_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm828","volume":"9","author":"E Song","year":"2003","unstructured":"Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347\u2013351 (2003).","journal-title":"Nat. Med."},{"key":"2112_CR14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067\u20131070 (2010).","journal-title":"Nature"},{"key":"2112_CR15","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Patisiran: First Global Approval. Drugs 78, 1625\u20131631 (2018).","journal-title":"Drugs"},{"key":"2112_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott, L. J. Givosiran: First Approval. Drugs 80, 335\u2013339 (2020).","journal-title":"Drugs"},{"key":"2112_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi, C. & Wood, M. J. A. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat. Rev. Neurol. 14, 9\u201321 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"2112_CR18","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Monia","year":"1993","unstructured":"Monia, B. P. et al. Evaluation of 2\u2019-modified oligonucleotides containing 2\u2019-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514\u201314522 (1993).","journal-title":"J. Biol. Chem."},{"key":"2112_CR19","doi-asserted-by":"publisher","first-page":"8955","DOI":"10.1093\/nar\/gkv920","volume":"43","author":"TA Vickers","year":"2015","unstructured":"Vickers, T. A. & Crooke, S. T. The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA. Nucleic Acids Res. 43, 8955\u20138963, (2015).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR20","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang, X. H., Sun, H., Nichols, J. G. & Crooke, S. T. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol. Ther. 25, 2075\u20132092 (2017).","journal-title":"Mol. Ther."},{"key":"2112_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/nar\/29.6.1293","volume":"29","author":"TA Vickers","year":"2001","unstructured":"Vickers, T. A. et al. Fully modified 2\u2019 MOE oligonucleotides redirect polyadenylation. Nucleic Acids Res. 29, 1293\u20131299 (2001).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/nar\/19.5.1113","volume":"19","author":"C Boiziau","year":"1991","unstructured":"Boiziau, C. et al. Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Res. 19, 1113\u20131119 (1991).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-genet-111212-133424","volume":"47","author":"MW Popp","year":"2013","unstructured":"Popp, M. W. & Maquat, L. E. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev. Genet. 47, 139\u2013165 (2013).","journal-title":"Annu Rev. Genet."},{"key":"2112_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nbt.3427","volume":"34","author":"TT Nomakuchi","year":"2016","unstructured":"Nomakuchi, T. T., Rigo, F., Aznarez, I. & Krainer, A. R. Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay. Nat. Biotechnol. 34, 164\u2013166 (2016).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev. Pharm. Toxicol. 50, 259\u2013293 (2010).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"2112_CR26","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 90, 8673\u20138677, (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR27","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen, X. & Corey, D. R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46, 1584\u20131600 (2018).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125\u2013140, (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR29","doi-asserted-by":"publisher","first-page":"12471","DOI":"10.1021\/acs.chemrev.3c00377","volume":"123","author":"C Ji","year":"2023","unstructured":"Ji, C. et al. Aptamer-Protein Interactions: From Regulation to Biomolecular Detection. Chem. Rev. 123, 12471\u201312506 (2023).","journal-title":"Chem. Rev."},{"key":"2112_CR30","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jacbts.2023.06.013","volume":"9","author":"V Di Mauro","year":"2024","unstructured":"Di Mauro, V. et al. Diagnostic and Therapeutic Aptamers: A Promising Pathway to Improved Cardiovascular Disease Management. JACC Basic Transl. Sci. 9, 260\u2013277 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"2112_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/nn507494p","volume":"9","author":"YH Lao","year":"2015","unstructured":"Lao, Y. H., Phua, K. K. & Leong, K. W. Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation. ACS Nano 9, 2235\u20132254, (2015).","journal-title":"ACS Nano"},{"key":"2112_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jcmm.12416","volume":"19","author":"C Oelkrug","year":"2015","unstructured":"Oelkrug, C. et al. Antibody- and aptamer-strategies for GvHD prevention. J. Cell Mol. Med. 19, 11\u201320 (2015).","journal-title":"J. Cell Mol. Med."},{"key":"2112_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jpba.2013.03.014","volume":"81-82","author":"T \u0160muc","year":"2013","unstructured":"\u0160muc, T., Ahn, I. Y. & Ulrich, H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J. Pharm. Biomed. Anal. 81-82, 210\u2013217 (2013).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2112_CR34","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1093\/nar\/gkv308","volume":"43","author":"J Hoinka","year":"2015","unstructured":"Hoinka, J. et al. Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucleic Acids Res. 43, 5699\u20135707 (2015).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR35","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1021\/acs.accounts.6b00283","volume":"49","author":"MR Gotrik","year":"2016","unstructured":"Gotrik, M. R. et al. Advancements in Aptamer Discovery Technologies. Acc. Chem. Res. 49, 1903\u20131910 (2016).","journal-title":"Acc. Chem. Res."},{"key":"2112_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.chroma.2014.08.073","volume":"1364","author":"Q Li","year":"2014","unstructured":"Li, Q., Zhao, X., Liu, H. & Qu, F. Low pH capillary electrophoresis application to improve capillary electrophoresis-systematic evolution of ligands by exponential enrichment. J. Chromatogr. A 1364, 289\u2013294 (2014).","journal-title":"J. Chromatogr. A"},{"key":"2112_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa484","volume":"48","author":"R Ishida","year":"2020","unstructured":"Ishida, R. et al. RaptRanker: in silico RNA aptamer selection from HT-SELEX experiment based on local sequence and structure information. Nucleic Acids Res. 48, e82 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nmat3765","volume":"12","author":"R Kanasty","year":"2013","unstructured":"Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967\u2013977, (2013).","journal-title":"Nat. Mater."},{"key":"2112_CR39","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","volume":"55","author":"I Ahn","year":"2023","unstructured":"Ahn, I., Kang, C. S. & Han, J. Where should siRNAs go: applicable organs for siRNA drugs. Exp. Mol. Med. 55, 1283\u20131292 (2023).","journal-title":"Exp. Mol. Med."},{"key":"2112_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0092-8674(03)00759-1","volume":"115","author":"DS Schwarz","year":"2003","unstructured":"Schwarz, D. S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199\u2013208 (2003).","journal-title":"Cell"},{"key":"2112_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu, B. et al. Therapeutic siRNA: state of the art. Signal Transduct. Target Ther. 5, 101 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2112_CR42","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1126\/science.1102513","volume":"305","author":"J Liu","year":"2004","unstructured":"Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437\u20131441 (2004).","journal-title":"Science"},{"key":"2112_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nsmb.2607","volume":"20","author":"N Sch\u00fcrmann","year":"2013","unstructured":"Sch\u00fcrmann, N. et al. Molecular dissection of human Argonaute proteins by DNA shuffling. Nat. Struct. Mol. Biol. 20, 818\u2013826 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2112_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-022-04790-2","volume":"607","author":"S Yamaguchi","year":"2022","unstructured":"Yamaguchi, S. et al. Structure of the Dicer-2-R2D2 heterodimer bound to a small RNA duplex. Nature 607, 393\u2013398 (2022).","journal-title":"Nature"},{"key":"2112_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molcel.2011.05.028","volume":"43","author":"CL Noland","year":"2011","unstructured":"Noland, C. L., Ma, E. & Doudna, J. A. siRNA repositioning for guide strand selection by human Dicer complexes. Mol. Cell 43, 110\u2013121, (2011).","journal-title":"Mol. Cell"},{"key":"2112_CR46","doi-asserted-by":"crossref","unstructured":"Masliah, G. et al. Structural basis of siRNA recognition by TRBP double-stranded RNA binding domains. Embo j. 37, (2018).","DOI":"10.15252\/embj.201797089"},{"key":"2112_CR47","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1093\/emboj\/20.23.6877","volume":"20","author":"SM Elbashir","year":"2001","unstructured":"Elbashir, S. M. et al. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo j. 20, 6877\u20136888 (2001).","journal-title":"Embo j."},{"key":"2112_CR48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrg3978","volume":"16","author":"A Wittrup","year":"2015","unstructured":"Wittrup, A. & Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543\u2013552, (2015).","journal-title":"Nat. Rev. Genet."},{"key":"2112_CR49","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1021\/acs.jmedchem.9b01839","volume":"63","author":"SC Humphreys","year":"2020","unstructured":"Humphreys, S. C. et al. Emerging siRNA Design Principles and Consequences for Biotransformation and Disposition in Drug Development. J. Med Chem. 63, 6407\u20136422 (2020).","journal-title":"J. Med Chem."},{"key":"2112_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1097-2765(02)00651-2","volume":"10","author":"DS Schwarz","year":"2002","unstructured":"Schwarz, D. S., Hutv\u00e1gner, G., Haley, B. & Zamore, P. D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 10, 537\u2013548 (2002).","journal-title":"Mol. Cell"},{"key":"2112_CR51","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0092-8674(02)00908-X","volume":"110","author":"J Martinez","year":"2002","unstructured":"Martinez, J. et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563\u2013574 (2002).","journal-title":"Cell"},{"key":"2112_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt1051","volume":"23","author":"DH Kim","year":"2005","unstructured":"Kim, D. H. et al. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat. Biotechnol. 23, 222\u2013226 (2005).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR53","first-page":"5238","volume":"12","author":"L Manche","year":"1992","unstructured":"Manche, L., Green, S. R., Schmedt, C. & Mathews, M. B. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol. Cell Biol. 12, 5238\u20135248 (1992).","journal-title":"Mol. Cell Biol."},{"key":"2112_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cytogfr.2007.06.016","volume":"18","author":"MP Gantier","year":"2007","unstructured":"Gantier, M. P. & Williams, B. R. The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev. 18, 363\u2013371 (2007).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2112_CR55","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nbt1151","volume":"23","author":"V Patzel","year":"2005","unstructured":"Patzel, V. et al. Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency. Nat. Biotechnol. 23, 1440\u20131444 (2005).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR56","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nmeth911","volume":"3","author":"Y Pei","year":"2006","unstructured":"Pei, Y. & Tuschl, T. On the art of identifying effective and specific siRNAs. Nat. Methods 3, 670\u2013676 (2006).","journal-title":"Nat. Methods"},{"key":"2112_CR57","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1102755","volume":"306","author":"Y Tomari","year":"2004","unstructured":"Tomari, Y. et al. A protein sensor for siRNA asymmetry. Science 306, 1377\u20131380 (2004).","journal-title":"Science"},{"key":"2112_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-1-62703-311-4_4","volume":"986","author":"S Petri","year":"2013","unstructured":"Petri, S. & Meister, G. siRNA design principles and off-target effects. Methods Mol. Biol. 986, 59\u201371 (2013).","journal-title":"Methods Mol. Biol."},{"key":"2112_CR59","doi-asserted-by":"publisher","first-page":"115052","DOI":"10.1016\/j.addr.2023.115052","volume":"201","author":"S Ranjbar","year":"2023","unstructured":"Ranjbar, S., Zhong, X. B., Manautou, J. & Lu, X. A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics. Adv. Drug Deliv. Rev. 201, 115052 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm1191","volume":"11","author":"V Hornung","year":"2005","unstructured":"Hornung, V. et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med 11, 263\u2013270 (2005).","journal-title":"Nat. Med"},{"key":"2112_CR61","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nbt1081","volume":"23","author":"AD Judge","year":"2005","unstructured":"Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457\u2013462 (2005).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR62","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov, Y. et al. Off-target effects by siRNA can induce toxic phenotype. Rna 12, 1188\u20131196 (2006).","journal-title":"Rna"},{"key":"2112_CR63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tig.2023.01.009","volume":"39","author":"D Pelletier","year":"2023","unstructured":"Pelletier, D., Rivera, B., Fabian, M. R. & Foulkes, W. D. miRNA biogenesis and inherited disorders: clinico-molecular insights. Trends Genet 39, 401\u2013414 (2023).","journal-title":"Trends Genet"},{"key":"2112_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cell.2008.10.053","volume":"136","author":"J Han","year":"2009","unstructured":"Han, J. et al. Posttranscriptional crossregulation between Drosha and DGCR8. Cell 136, 75\u201384 (2009).","journal-title":"Cell"},{"key":"2112_CR65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/science.1090599","volume":"303","author":"E Lund","year":"2004","unstructured":"Lund, E. et al. Nuclear export of microRNA precursors. Science 303, 95\u201398 (2004).","journal-title":"Science"},{"key":"2112_CR66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrm3838","volume":"15","author":"M Ha","year":"2014","unstructured":"Ha, M. & Kim, V. N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509\u2013524 (2014).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41586-023-05723-3","volume":"615","author":"YY Lee","year":"2023","unstructured":"Lee, Y. Y. et al. Structure of the human DICER-pre-miRNA complex in a dicing state. Nature 615, 331\u2013338 (2023).","journal-title":"Nature"},{"key":"2112_CR68","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","volume":"20","author":"T Treiber","year":"2019","unstructured":"Treiber, T., Treiber, N. & Meister, G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat. Rev. Mol. Cell Biol. 20, 5\u201320 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle, M., El-Daly, S. M., Fabbri, M. & Calin, G. A. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov. 20, 629\u2013651 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR70","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-022-01298-z","volume":"8","author":"ZG Lu","year":"2023","unstructured":"Lu, Z. G. et al. Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct. Target Ther. 8, 39 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2112_CR71","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1002\/cncr.25488","volume":"116","author":"S Majid","year":"2010","unstructured":"Majid, S. et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116, 5637\u20135649 (2010).","journal-title":"Cancer"},{"key":"2112_CR72","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1093\/nar\/gkt777","volume":"41","author":"M Matsui","year":"2013","unstructured":"Matsui, M. et al. Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res 41, 10086\u201310109 (2013).","journal-title":"Nucleic Acids Res"},{"key":"2112_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4161\/cc.27679","volume":"13","author":"MJ Turner","year":"2014","unstructured":"Turner, M. J., Jiao, A. L. & Slack, F. J. Autoregulation of lin-4 microRNA transcription by RNA activation (RNAa) in C. elegans. Cell Cycle 13, 772\u2013781 (2014).","journal-title":"Cell Cycle"},{"key":"2112_CR74","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/15476286.2015.1112487","volume":"14","author":"M Xiao","year":"2017","unstructured":"Xiao, M. et al. MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 14, 1326\u20131334 (2017).","journal-title":"RNA Biol."},{"key":"2112_CR75","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/gt.2011.79","volume":"18","author":"AG Bader","year":"2011","unstructured":"Bader, A. G., Brown, D., Stoudemire, J. & Lammers, P. Developing therapeutic microRNAs for cancer. Gene Ther. 18, 1121\u20131126, (2011).","journal-title":"Gene Ther."},{"key":"2112_CR76","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2013.04.003","volume":"153","author":"LA Yates","year":"2013","unstructured":"Yates, L. A., Norbury, C. J. & Gilbert, R. J. The long and short of microRNA. Cell 153, 516\u2013519 (2013).","journal-title":"Cell"},{"key":"2112_CR77","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cell.2013.03.043","volume":"153","author":"A Helwak","year":"2013","unstructured":"Helwak, A., Kudla, G., Dudnakova, T. & Tollervey, D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 153, 654\u2013665, (2013).","journal-title":"Cell"},{"key":"2112_CR78","doi-asserted-by":"publisher","first-page":"12169","DOI":"10.1093\/nar\/gku854","volume":"42","author":"S Gu","year":"2014","unstructured":"Gu, S. et al. Weak base pairing in both seed and 3\u2019 regions reduces RNAi off-targets and enhances si\/shRNA designs. Nucleic Acids Res. 42, 12169\u201312176 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR79","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.molcel.2007.05.001","volume":"26","author":"L Peters","year":"2007","unstructured":"Peters, L. & Meister, G. Argonaute proteins: mediators of RNA silencing. Mol. Cell 26, 611\u2013623, (2007).","journal-title":"Mol. Cell"},{"key":"2112_CR80","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nature04916","volume":"442","author":"A Aravin","year":"2006","unstructured":"Aravin, A. et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature 442, 203\u2013207 (2006).","journal-title":"Nature"},{"key":"2112_CR81","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nature04917","volume":"442","author":"A Girard","year":"2006","unstructured":"Girard, A., Sachidanandam, R., Hannon, G. J. & Carmell, M. A. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 442, 199\u2013202 (2006).","journal-title":"Nature"},{"key":"2112_CR82","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.1130164","volume":"313","author":"NC Lau","year":"2006","unstructured":"Lau, N. C. et al. Characterization of the piRNA complex from rat testes. Science 313, 363\u2013367 (2006).","journal-title":"Science"},{"key":"2112_CR83","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1101\/gad.1454806","volume":"20","author":"K Saito","year":"2006","unstructured":"Saito, K. et al. Specific association of Piwi with rasiRNAs derived from retrotransposon and heterochromatic regions in the Drosophila genome. Genes Dev. 20, 2214\u20132222 (2006).","journal-title":"Genes Dev."},{"key":"2112_CR84","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1101\/gad.1434406","volume":"20","author":"ST Grivna","year":"2006","unstructured":"Grivna, S. T., Beyret, E., Wang, Z. & Lin, H. A novel class of small RNAs in mouse spermatogenic cells. Genes Dev. 20, 1709\u20131714 (2006).","journal-title":"Genes Dev."},{"key":"2112_CR85","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nature11509","volume":"491","author":"H Nishimasu","year":"2012","unstructured":"Nishimasu, H. et al. Structure and function of Zucchini endoribonuclease in piRNA biogenesis. Nature 491, 284\u2013287 (2012).","journal-title":"Nature"},{"key":"2112_CR86","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-021-01104-3","volume":"14","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. The biogenesis and biological function of PIWI-interacting RNA in cancer. J. Hematol. Oncol. 14, 93 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2112_CR87","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.cell.2009.10.042","volume":"139","author":"JS Tushir","year":"2009","unstructured":"Tushir, J. S., Zamore, P. D. & Zhang, Z. SnapShot: mouse piRNAs, PIWI proteins, and the ping-pong cycle. Cell 139, 830\u2013830.e831 (2009).","journal-title":"Cell"},{"key":"2112_CR88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2007.03.026","volume":"129","author":"S Houwing","year":"2007","unstructured":"Houwing, S. et al. A role for Piwi and piRNAs in germ cell maintenance and transposon silencing in Zebrafish. Cell 129, 69\u201382 (2007).","journal-title":"Cell"},{"key":"2112_CR89","doi-asserted-by":"publisher","first-page":"32824","DOI":"10.1074\/jbc.M114.613232","volume":"289","author":"N Ortogero","year":"2014","unstructured":"Ortogero, N. et al. A novel class of somatic small RNAs similar to germ cell pachytene PIWI-interacting small RNAs. J. Biol. Chem. 289, 32824\u201332834 (2014).","journal-title":"J. Biol. Chem."},{"key":"2112_CR90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.celrep.2014.12.013","volume":"10","author":"KM Nishida","year":"2015","unstructured":"Nishida, K. M. et al. Respective functions of two distinct Siwi complexes assembled during PIWI-interacting RNA biogenesis in Bombyx germ cells. Cell Rep. 10, 193\u2013203 (2015).","journal-title":"Cell Rep."},{"key":"2112_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04429-7","volume":"7","author":"S Honda","year":"2017","unstructured":"Honda, S. et al. Increasing cell density globally enhances the biogenesis of Piwi-interacting RNAs in Bombyx mori germ cells. Sci. Rep. 7, 4110 (2017).","journal-title":"Sci. Rep."},{"key":"2112_CR92","doi-asserted-by":"publisher","first-page":"13415","DOI":"10.1073\/pnas.0605506103","volume":"103","author":"ST Grivna","year":"2006","unstructured":"Grivna, S. T., Pyhtila, B. & Lin, H. MIWI associates with translational machinery and PIWI-interacting RNAs (piRNAs) in regulating spermatogenesis. Proc. Natl. Acad. Sci. USA 103, 13415\u201313420 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR93","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.devcel.2022.01.001","volume":"57","author":"AG Charlesworth","year":"2022","unstructured":"Charlesworth, A. G., Nitschko, V., Renaud, M. S. & Claycomb, J. M. PIWI puts spermatogenesis in its place. Dev. Cell 57, 149\u2013151 (2022).","journal-title":"Dev. Cell"},{"key":"2112_CR94","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrm3089","volume":"12","author":"MC Siomi","year":"2011","unstructured":"Siomi, M. C., Sato, K., Pezic, D. & Aravin, A. A. PIWI-interacting small RNAs: the vanguard of genome defence. Nat. Rev. Mol. Cell Biol. 12, 246\u2013258, (2011).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR95","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41586-023-06257-4","volume":"619","author":"I Gainetdinov","year":"2023","unstructured":"Gainetdinov, I. et al. Relaxed targeting rules help PIWI proteins silence transposons. Nature 619, 394\u2013402 (2023).","journal-title":"Nature"},{"key":"2112_CR96","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/cas.13300","volume":"108","author":"J Yin","year":"2017","unstructured":"Yin, J. et al. piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1. Cancer Sci. 108, 1746\u20131756 (2017).","journal-title":"Cancer Sci."},{"key":"2112_CR97","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/jmedgenet-2021-108327","volume":"59","author":"L Xiao","year":"2022","unstructured":"Xiao, L. et al. Disorders and roles of tsRNA, snoRNA, snRNA and piRNA in cancer. J. Med Genet. 59, 623\u2013631 (2022).","journal-title":"J. Med Genet."},{"key":"2112_CR98","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1080\/15384101.2021.1956090","volume":"20","author":"T Liu","year":"2021","unstructured":"Liu, T. et al. Piwi-interacting RNA-651 promotes cell proliferation and migration and inhibits apoptosis in breast cancer by facilitating DNMT1-mediated PTEN promoter methylation. Cell Cycle 20, 1603\u20131616 (2021).","journal-title":"Cell Cycle"},{"key":"2112_CR99","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2011.10.004","volume":"315","author":"J Cheng","year":"2012","unstructured":"Cheng, J. et al. piR-823, a novel non-coding small RNA, demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells. Cancer Lett. 315, 12\u201317 (2012).","journal-title":"Cancer Lett."},{"key":"2112_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04922-6","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. piR-823 inhibits cell apoptosis via modulating mitophagy by binding to PINK1 in colorectal cancer. Cell Death Dis. 13, 465 (2022).","journal-title":"Cell Death Dis."},{"key":"2112_CR101","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.omtn.2017.12.020","volume":"10","author":"S Shen","year":"2018","unstructured":"Shen, S. et al. PIWIL1\/piRNA-DQ593109 Regulates the Permeability of the Blood-Tumor Barrier via the MEG3\/miR-330-5p\/RUNX3 Axis. Mol. Ther. Nucleic Acids 10, 412\u2013425 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0940-3","volume":"18","author":"L Tan","year":"2019","unstructured":"Tan, L. et al. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol. Cancer 18, 9 (2019).","journal-title":"Mol. Cancer"},{"key":"2112_CR103","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ng.2007.55","volume":"40","author":"A Visel","year":"2008","unstructured":"Visel, A. et al. Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nat. Genet 40, 158\u2013160 (2008).","journal-title":"Nat. Genet"},{"key":"2112_CR104","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature05295","volume":"444","author":"LA Pennacchio","year":"2006","unstructured":"Pennacchio, L. A. et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature 444, 499\u2013502 (2006).","journal-title":"Nature"},{"key":"2112_CR105","doi-asserted-by":"publisher","first-page":"17337","DOI":"10.1073\/pnas.0607015103","volume":"103","author":"LC Li","year":"2006","unstructured":"Li, L. C. et al. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 103, 17337\u201317342 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR106","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","volume":"380","author":"AA Levin","year":"2019","unstructured":"Levin, A. A. Treating Disease at the RNA Level with Oligonucleotides. N. Engl. J. Med. 380, 57\u201370 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR107","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nsmb1092","volume":"13","author":"TR Hartman","year":"2006","unstructured":"Hartman, T. R. et al. RNA helicase A is necessary for translation of selected messenger RNAs. Nat. Struct. Mol. Biol. 13, 509\u2013516 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2112_CR108","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cell.2008.12.023","volume":"136","author":"L Weinmann","year":"2009","unstructured":"Weinmann, L. et al. Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs. Cell 136, 496\u2013507 (2009).","journal-title":"Cell"},{"key":"2112_CR109","doi-asserted-by":"publisher","first-page":"10270","DOI":"10.1074\/jbc.C113.541417","volume":"289","author":"Y Wei","year":"2014","unstructured":"Wei, Y. et al. Importin 8 regulates the transport of mature microRNAs into the cell nucleus. J. Biol. Chem. 289, 10270\u201310275 (2014).","journal-title":"J. Biol. Chem."},{"key":"2112_CR110","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/cr.2016.22","volume":"26","author":"V Portnoy","year":"2016","unstructured":"Portnoy, V. et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 26, 320\u2013335 (2016).","journal-title":"Cell Res."},{"key":"2112_CR111","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cell.2009.12.050","volume":"140","author":"J Kim","year":"2010","unstructured":"Kim, J., Guermah, M. & Roeder, R. G. The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII\/TFIIS. Cell 140, 491\u2013503 (2010).","journal-title":"Cell"},{"key":"2112_CR112","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nchembio.400","volume":"6","author":"X Yue","year":"2010","unstructured":"Yue, X. et al. Transcriptional regulation by small RNAs at sequences downstream from 3\u2019 gene termini. Nat. Chem. Biol. 6, 621\u2013629 (2010).","journal-title":"Nat. Chem. Biol."},{"key":"2112_CR113","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2014.09.004","volume":"355","author":"L Zheng","year":"2014","unstructured":"Zheng, L., Wang, L., Gan, J. & Zhang, H. RNA activation: promise as a new weapon against cancer. Cancer Lett. 355, 18\u201324 (2014).","journal-title":"Cancer Lett."},{"key":"2112_CR114","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nchembio860","volume":"3","author":"BA Janowski","year":"2007","unstructured":"Janowski, B. A. et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3, 166\u2013173 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"2112_CR115","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1093\/nar\/gkq258","volume":"38","author":"JK Watts","year":"2010","unstructured":"Watts, J. K. et al. Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res 38, 5242\u20135259 (2010).","journal-title":"Nucleic Acids Res"},{"key":"2112_CR116","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2174\/1389201019666180611093428","volume":"19","author":"RL Setten","year":"2018","unstructured":"Setten, R. L., Lightfoot, H. L., Habib, N. A. & Rossi, J. J. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma. Curr. Pharm. Biotechnol. 19, 611\u2013621 (2018).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"2112_CR117","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/d41573-021-00127-2","volume":"20","author":"K Kingwell","year":"2021","unstructured":"Kingwell, K. Small activating RNAs lead the charge to turn up gene expression. Nat. Rev. Drug Discov. 20, 573\u2013574 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR118","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","volume":"51","author":"M Egli","year":"2023","unstructured":"Egli, M. & Manoharan, M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 51, 2529\u20132573 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR119","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nrd837","volume":"1","author":"JB Opalinska","year":"2002","unstructured":"Opalinska, J. B. & Gewirtz, A. M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503\u2013514, (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR120","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","volume":"59","author":"WB Wan","year":"2016","unstructured":"Wan, W. B. & Seth, P. P. The Medicinal Chemistry of Therapeutic Oligonucleotides. J. Med Chem. 59, 9645\u20139667 (2016).","journal-title":"J. Med Chem."},{"key":"2112_CR121","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46\u201351 (2015).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR122","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1093\/nar\/gkp106","volume":"37","author":"JB Bramsen","year":"2009","unstructured":"Bramsen, J. B. et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37, 2867\u20132881 (2009).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR123","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/hep.20702","volume":"41","author":"DV Morrissey","year":"2005","unstructured":"Morrissey, D. V. et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41, 1349\u20131356 (2005).","journal-title":"Hepatology"},{"key":"2112_CR124","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","volume":"266","author":"Y Sato","year":"2017","unstructured":"Sato, Y. et al. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus. J. Control Release 266, 216\u2013225 (2017).","journal-title":"J. Control Release"},{"key":"2112_CR125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2013.10.023","volume":"173","author":"H Hatakeyama","year":"2014","unstructured":"Hatakeyama, H. et al. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J. Control Release 173, 43\u201350 (2014).","journal-title":"J. Control Release"},{"key":"2112_CR126","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","volume":"25","author":"J Voutila","year":"2017","unstructured":"Voutila, J. et al. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer. Mol. Ther. 25, 2705\u20132714 (2017).","journal-title":"Mol. Ther."},{"key":"2112_CR127","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178\u20132185 (2011).","journal-title":"Mol. Ther."},{"key":"2112_CR128","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1021\/jacs.7b02694","volume":"139","author":"MK Schlegel","year":"2017","unstructured":"Schlegel, M. K. et al. Chirality Dependent Potency Enhancement and Structural Impact of Glycol Nucleic Acid Modification on siRNA. J. Am. Chem. Soc. 139, 8537\u20138546 (2017).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR129","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/mt.2009.91","volume":"17","author":"S Gao","year":"2009","unstructured":"Gao, S. et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225\u20131233 (2009).","journal-title":"Mol. Ther."},{"key":"2112_CR130","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1038\/mtna.2013.36","volume":"2","author":"NM Snead","year":"2013","unstructured":"Snead, N. M., Escamilla-Powers, J. R., Rossi, J. J. & McCaffrey, A. P. 5\u2019 Unlocked Nucleic Acid Modification Improves siRNA Targeting. Mol. Ther. Nucleic Acids 2, e103 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR131","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nature13802","volume":"515","author":"TM Carlile","year":"2014","unstructured":"Carlile, T. M. et al. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 515, 143\u2013146 (2014).","journal-title":"Nature"},{"key":"2112_CR132","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.omtn.2023.05.004","volume":"32","author":"MC Bernard","year":"2023","unstructured":"Bernard, M. C. et al. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system. Mol. Ther. Nucleic Acids 32, 794\u2013806 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR133","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175, (2005).","journal-title":"Immunity"},{"key":"2112_CR134","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.omtn.2018.06.010","volume":"12","author":"S Vaidyanathan","year":"2018","unstructured":"Vaidyanathan, S. et al. Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification. Mol. Ther. Nucleic Acids 12, 530\u2013542 (2018).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR135","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1021\/jacs.5b00445","volume":"137","author":"BD Heuberger","year":"2015","unstructured":"Heuberger, B. D. et al. Replacing uridine with 2-thiouridine enhances the rate and fidelity of nonenzymatic RNA primer extension. J. Am. Chem. Soc. 137, 2769\u20132775 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR136","doi-asserted-by":"publisher","first-page":"e85324","DOI":"10.7554\/eLife.85324","volume":"12","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. The landscape of m(1)A modification and its posttranscriptional regulatory functions in primary neurons. Elife 12, e85324 (2023).","journal-title":"Elife"},{"key":"2112_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02147-z","volume":"21","author":"Ali Zaidi","year":"2023","unstructured":"Zaidi, Ali et al. Engineering siRNA therapeutics: challenges and strategies. J. Nanobiotechnol. 21, 381 (2023).","journal-title":"J. Nanobiotechnol."},{"key":"2112_CR138","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.omtn.2018.12.007","volume":"14","author":"J Lockhart","year":"2019","unstructured":"Lockhart, J. et al. Nucleotide Modification Alters MicroRNA-Dependent Silencing of MicroRNA Switches. Mol. Ther. Nucleic Acids 14, 339\u2013350 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR139","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1002\/cbic.201200349","volume":"13","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects. Chembiochem 13, 1940\u20131945 (2012).","journal-title":"Chembiochem"},{"key":"2112_CR140","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1093\/nar\/gkf412","volume":"30","author":"D Renneberg","year":"2002","unstructured":"Renneberg, D. et al. Antisense properties of tricyclo-DNA. Nucleic Acids Res. 30, 2751\u20132757 (2002).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR141","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","volume":"48","author":"L Sheng","year":"2020","unstructured":"Sheng, L. et al. Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model. Nucleic Acids Res. 48, 2853\u20132865 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR142","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0959-440X(95)80096-4","volume":"5","author":"A De Mesmaeker","year":"1995","unstructured":"De Mesmaeker, A., Altmann, K. H., Waldner, A. & Wendeborn, S. Backbone modifications in oligonucleotides and peptide nucleic acid systems. Curr. Opin. Struct. Biol. 5, 343\u2013355, (1995).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2112_CR143","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.1073\/pnas.1409431111","volume":"111","author":"SN Barnaby","year":"2014","unstructured":"Barnaby, S. N., Lee, A. & Mirkin, C. A. Probing the inherent stability of siRNA immobilized on nanoparticle constructs. Proc. Natl. Acad. Sci. USA 111, 9739\u20139744, (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7317","volume":"6","author":"H Jahns","year":"2015","unstructured":"Jahns, H. et al. Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs. Nat. Commun. 6, 6317 (2015).","journal-title":"Nat. Commun."},{"key":"2112_CR145","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/nar\/21.9.2031","volume":"21","author":"RI Hogrefe","year":"1993","unstructured":"Hogrefe, R. I. et al. Deprotection of methylphosphonate oligonucleotides using a novel one-pot procedure. Nucleic Acids Res. 21, 2031\u20132038 (1993).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR146","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1089\/nat.2021.0064","volume":"32","author":"G Vasquez","year":"2022","unstructured":"Vasquez, G. et al. Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides. Nucleic Acid Ther. 32, 40\u201350 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR147","doi-asserted-by":"publisher","first-page":"10508","DOI":"10.1039\/C7CC05722A","volume":"53","author":"X Yang","year":"2017","unstructured":"Yang, X., Dinuka Abeydeera, N., Liu, F. W. & Egli, M. Origins of the enhanced affinity of RNA-protein interactions triggered by RNA phosphorodithioate backbone modification. Chem. Commun. (Camb.) 53, 10508\u201310511 (2017).","journal-title":"Chem. Commun. (Camb.)"},{"key":"2112_CR148","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1021\/ja044964s","volume":"127","author":"H Torigoe","year":"2005","unstructured":"Torigoe, H. & Maruyama, A. Synergistic stabilization of nucleic acid assembly by oligo-N3\u2019->P5\u2019 phosphoramidate modification and additions of comb-type cationic copolymers. J. Am. Chem. Soc. 127, 1705\u20131710 (2005).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR149","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1093\/nar\/27.21.4151","volume":"27","author":"A Laurent","year":"1999","unstructured":"Laurent, A. et al. Chiral and steric effects in the efficient binding of alpha-anomeric deoxyoligonucleoside N-alkylphosphoramidates to ssDNA and RNA. Nucleic Acids Res. 27, 4151\u20134159 (1999).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR150","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/nprot.2007.74","volume":"2","author":"PS Pallan","year":"2007","unstructured":"Pallan, P. S. & Egli, M. Selenium modification of nucleic acids: preparation of phosphoroselenoate derivatives for crystallographic phasing of nucleic acid structures. Nat. Protoc. 2, 640\u2013646, (2007).","journal-title":"Nat. Protoc."},{"key":"2112_CR151","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3078","volume":"32","author":"BR Meade","year":"2014","unstructured":"Meade, B. R. et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol. 32, 1256\u20131261 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR152","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1093\/nar\/gkh936","volume":"32","author":"AH Hall","year":"2004","unstructured":"Hall, A. H. et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 32, 5991\u20136000 (2004).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR153","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/jo001699u","volume":"66","author":"H An","year":"2001","unstructured":"An, H. et al. Synthesis of novel 3\u2019-C-methylene thymidine and 5-methyluridine\/cytidine H-phosphonates and phosphonamidites for new backbone modification of oligonucleotides. J. Org. Chem. 66, 2789\u20132801 (2001).","journal-title":"J. Org. Chem."},{"key":"2112_CR154","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1073\/pnas.92.13.5798","volume":"92","author":"SM Gryaznov","year":"1995","unstructured":"Gryaznov, S. M. et al. Oligonucleotide N3\u2019->P5\u2019 phosphoramidates. Proc. Natl. Acad. Sci. USA 92, 5798\u20135802 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR155","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1093\/nar\/gku235","volume":"42","author":"D Mutisya","year":"2014","unstructured":"Mutisya, D. et al. Amides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAs. Nucleic Acids Res. 42, 6542\u20136551 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR156","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1080\/07328319908044723","volume":"18","author":"LM Cowsert","year":"1999","unstructured":"Cowsert, L. M. et al. MMI linkage modification increases potency and stability of H-ras antisense oligonucleotides. Nucleosides Nucleotides 18, 1383\u20131384 (1999).","journal-title":"Nucleosides Nucleotides"},{"key":"2112_CR157","doi-asserted-by":"publisher","first-page":"14932","DOI":"10.1021\/ja904926e","volume":"131","author":"A Kolarovic","year":"2009","unstructured":"Kolarovic, A. et al. Interplay of structure, hydration and thermal stability in formacetal modified oligonucleotides: RNA may tolerate nonionic modifications better than DNA. J. Am. Chem. Soc. 131, 14932\u201314937 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR158","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1021\/bi961760i","volume":"36","author":"JS Rice","year":"1997","unstructured":"Rice, J. S. & Gao, X. Conformation of formacetal and 3\u2019-thioformacetal nucleotide linkers and stability of their antisense RNA.DNA hybrid duplexes. Biochemistry 36, 399\u2013411 (1997).","journal-title":"Biochemistry"},{"key":"2112_CR159","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","volume":"25","author":"SM Freier","year":"1997","unstructured":"Freier, S. M. & Altmann, K. H. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429\u20134443 (1997).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR160","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/nar\/gkab544","volume":"50","author":"H Jahns","year":"2022","unstructured":"Jahns, H. et al. Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo. Nucleic Acids Res. 50, 1221\u20131240 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR161","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 35, 845\u2013851 (2017).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR162","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/nar\/gkaa031","volume":"48","author":"ME \u00d8stergaard","year":"2020","unstructured":"\u00d8stergaard, M. E. et al. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res. 48, 1691\u20131700 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR163","doi-asserted-by":"publisher","first-page":"13456","DOI":"10.1093\/nar\/gku1115","volume":"42","author":"WB Wan","year":"2014","unstructured":"Wan, W. B. et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res. 42, 13456\u201313468 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR164","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1167\/tvst.10.1.23","volume":"10","author":"M Byrne","year":"2021","unstructured":"Byrne, M. et al. Stereochemistry Enhances Potency, Efficacy, and Durability of Malat1 Antisense Oligonucleotides In Vitro and In Vivo in Multiple Species. Transl. Vis. Sci. Technol. 10, 23 (2021).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"2112_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4459","volume":"5","author":"SY Wu","year":"2014","unstructured":"Wu, S. Y. et al. 2\u2019-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun. 5, 3459 (2014).","journal-title":"Nat. Commun."},{"key":"2112_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31636-2","volume":"13","author":"YR Baker","year":"2022","unstructured":"Baker, Y. R. et al. An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides. Nat. Commun. 13, 4036 (2022).","journal-title":"Nat. Commun."},{"key":"2112_CR167","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen, W. et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat. Biotechnol. 37, 640\u2013650 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR168","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.20140391","volume":"212","author":"U Flierl","year":"2015","unstructured":"Flierl, U. et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J. Exp. Med. 212, 129\u2013137 (2015).","journal-title":"J. Exp. Med."},{"key":"2112_CR169","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/nar\/gkl1071","volume":"35","author":"EE Swayze","year":"2007","unstructured":"Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687\u2013700 (2007).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR170","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1093\/nar\/gku142","volume":"42","author":"AD Burdick","year":"2014","unstructured":"Burdick, A. D. et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res. 42, 4882\u20134891 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR171","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijpharm.2011.02.001","volume":"417","author":"J Kuntsche","year":"2011","unstructured":"Kuntsche, J., Horst, J. C. & Bunjes, H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J. Pharm. 417, 120\u2013137 (2011).","journal-title":"Int J. Pharm."},{"key":"2112_CR172","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202303266","volume":"36","author":"M Hu","year":"2024","unstructured":"Hu, M. et al. Physiological Barriers and Strategies of Lipid-Based Nanoparticles for Nucleic Acid Drug Delivery. Adv. Mater. 36, e2303266 (2024).","journal-title":"Adv. Mater."},{"key":"2112_CR173","doi-asserted-by":"publisher","first-page":"102930","DOI":"10.1016\/j.cis.2023.102930","volume":"317","author":"S Kans\u0131z","year":"2023","unstructured":"Kans\u0131z, S. & El\u00e7in, Y. M. Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches. Adv. Colloid Interface Sci. 317, 102930 (2023).","journal-title":"Adv. Colloid Interface Sci."},{"key":"2112_CR174","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","volume":"13","author":"AD Bangham","year":"1965","unstructured":"Bangham, A. D., Standish, M. M. & Watkins, J. C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13, 238\u2013252, (1965).","journal-title":"J. Mol. Biol."},{"key":"2112_CR175","doi-asserted-by":"publisher","first-page":"58p","DOI":"10.1042\/bj1240058P","volume":"124","author":"G Gregoriadis","year":"1971","unstructured":"Gregoriadis, G. & Ryman, B. E. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J. 124, 58p (1971).","journal-title":"Biochem J."},{"key":"2112_CR176","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/337387a0","volume":"337","author":"PL Felgner","year":"1989","unstructured":"Felgner, P. L. & Ringold, G. M. Cationic liposome-mediated transfection. Nature 337, 387\u2013388, (1989).","journal-title":"Nature"},{"key":"2112_CR177","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/0092-8674(91)90647-H","volume":"64","author":"CV Harding","year":"1991","unstructured":"Harding, C. V. et al. Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells. Cell 64, 393\u2013401 (1991).","journal-title":"Cell"},{"key":"2112_CR178","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone, R. W., Felgner, P. L. & Verma, I. M. Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA 86, 6077\u20136081, (1989).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2112_CR179","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.1158\/1078-0432.CCR-04-1049","volume":"10","author":"J Yano","year":"2004","unstructured":"Yano, J. et al. Antitumor activity of small interfering RNA\/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721\u20137726 (2004).","journal-title":"Clin. Cancer Res."},{"key":"2112_CR180","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.plipres.2008.03.002","volume":"47","author":"C Lonez","year":"2008","unstructured":"Lonez, C., Vandenbranden, M. & Ruysschaert, J. M. Cationic liposomal lipids: from gene carriers to cell signaling. Prog. Lipid Res. 47, 340\u2013347, (2008).","journal-title":"Prog. Lipid Res."},{"key":"2112_CR181","doi-asserted-by":"publisher","first-page":"32006","DOI":"10.1021\/acsami.8b12393","volume":"10","author":"Y Qian","year":"2018","unstructured":"Qian, Y. et al. Hyaluronan Reduces Cationic Liposome-Induced Toxicity and Enhances the Antitumor Effect of Targeted Gene Delivery in Mice. ACS Appl Mater. Interf. 10, 32006\u201332016 (2018).","journal-title":"ACS Appl Mater. Interf."},{"key":"2112_CR182","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1158\/0008-5472.CAN-08-2397","volume":"68","author":"GJ Villares","year":"2008","unstructured":"Villares, G. J. et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 68, 9078\u20139086 (2008).","journal-title":"Cancer Res."},{"key":"2112_CR183","doi-asserted-by":"publisher","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","volume":"121","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Lipids and Lipid Derivatives for RNA Delivery. Chem. Rev. 121, 12181\u201312277 (2021).","journal-title":"Chem. Rev."},{"key":"2112_CR184","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.addr.2023.114990","volume":"200","author":"M Jeong","year":"2023","unstructured":"Jeong, M. et al. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR185","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.omtn.2020.01.018","volume":"19","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo. Mol. Ther. Nucleic Acids 19, 1357\u20131367 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR186","doi-asserted-by":"publisher","first-page":"20230147","DOI":"10.1002\/EXP.20230147","volume":"4","author":"Y Ma","year":"2024","unstructured":"Ma, Y., Li, S., Lin, X. & Chen, Y. A perspective of lipid nanoparticles for RNA delivery. Exploration 4, 20230147 (2024).","journal-title":"Exploration"},{"key":"2112_CR187","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084\u20131087 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"2112_CR188","doi-asserted-by":"publisher","first-page":"18759","DOI":"10.1016\/S0021-9258(19)37026-7","volume":"267","author":"A Chonn","year":"1992","unstructured":"Chonn, A., Semple, S. C. & Cullis, P. R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 267, 18759\u201318765, (1992).","journal-title":"J. Biol. Chem."},{"key":"2112_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR190","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","volume":"27","author":"Y Nakamura","year":"2016","unstructured":"Nakamura, Y., Mochida, A., Choyke, P. L. & Kobayashi, H. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjug. Chem. 27, 2225\u20132238 (2016).","journal-title":"Bioconjug. Chem."},{"key":"2112_CR191","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis, P. R. & Hope, M. J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 25, 1467\u20131475 (2017).","journal-title":"Mol. Ther."},{"key":"2112_CR192","doi-asserted-by":"publisher","first-page":"e10213","DOI":"10.1002\/btm2.10213","volume":"6","author":"M Schlich","year":"2021","unstructured":"Schlich, M. et al. Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 6, e10213 (2021).","journal-title":"Bioeng. Transl. Med."},{"key":"2112_CR193","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int Ed. Engl. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR194","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","volume":"31","author":"R Kedmi","year":"2010","unstructured":"Kedmi, R., Ben-Arie, N. & Peer, D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867\u20136875, (2010).","journal-title":"Biomaterials"},{"key":"2112_CR195","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","volume":"154-155","author":"E Samaridou","year":"2020","unstructured":"Samaridou, E., Heyes, J. & Lutwyche, P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv. Drug Deliv. Rev. 154-155, 37\u201363 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR196","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc. Chem. Res 55, 2\u201312 (2022).","journal-title":"Acc. Chem. Res"},{"key":"2112_CR197","first-page":"371","volume":"5","author":"T Gjetting","year":"2010","unstructured":"Gjetting, T. et al. In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP\/cholesterol-mediated gene transfection. Int J. Nanomed. 5, 371\u2013383, (2010).","journal-title":"Int J. Nanomed."},{"key":"2112_CR198","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41375-023-01854-8","volume":"37","author":"H Issa","year":"2023","unstructured":"Issa, H. et al. Nanoparticle-mediated targeting of the fusion gene RUNX1\/ETO in t(8;21)-positive acute myeloid leukaemia. Leukemia 37, 820\u2013834 (2023).","journal-title":"Leukemia"},{"key":"2112_CR199","doi-asserted-by":"publisher","first-page":"119792","DOI":"10.1016\/j.ijpharm.2020.119792","volume":"588","author":"T Suzuki","year":"2020","unstructured":"Suzuki, T. et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production. Int J. Pharm. 588, 119792 (2020).","journal-title":"Int J. Pharm."},{"key":"2112_CR200","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1038\/mtna.2012.28","volume":"1","author":"NM Belliveau","year":"2012","unstructured":"Belliveau, N. M. et al. Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol. Ther. Nucleic Acids 1, e37 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211420","volume":"35","author":"K Lam","year":"2023","unstructured":"Lam, K. et al. Optimizing Lipid Nanoparticles for Delivery in Primates. Adv. Mater. 35, e2211420 (2023).","journal-title":"Adv. Mater."},{"key":"2112_CR202","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1021\/ar500260t","volume":"47","author":"MR Krause","year":"2014","unstructured":"Krause, M. R. & Regen, S. L. The structural role of cholesterol in cell membranes: from condensed bilayers to lipid rafts. Acc. Chem. Res 47, 3512\u20133521, (2014).","journal-title":"Acc. Chem. Res"},{"key":"2112_CR203","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"2112_CR204","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14527-2","volume":"11","author":"S Patel","year":"2020","unstructured":"Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).","journal-title":"Nat. Commun."},{"key":"2112_CR205","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","volume":"99","author":"X Cheng","year":"2016","unstructured":"Cheng, X. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 99, 129\u2013137 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR206","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1021\/ja301621z","volume":"134","author":"D Chen","year":"2012","unstructured":"Chen, D. et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948\u20136951 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR207","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","volume":"344","author":"M Maeki","year":"2022","unstructured":"Maeki, M. et al. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J. Control Release 344, 80\u201396 (2022).","journal-title":"J. Control Release"},{"key":"2112_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2023.464375","volume":"1709","author":"KH Kim","year":"2023","unstructured":"Kim, K. H. et al. Optimization of HPLCCAD method for simultaneous analysis of different lipids in lipid nanoparticles with analytical QbD. J. Chromatogr. A 1709, 464375 (2023).","journal-title":"J. Chromatogr. A"},{"key":"2112_CR209","doi-asserted-by":"publisher","first-page":"13993","DOI":"10.1021\/acsnano.1c05099","volume":"15","author":"JP Bost","year":"2021","unstructured":"Bost, J. P. et al. Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. ACS Nano 15, 13993\u201314021 (2021).","journal-title":"ACS Nano"},{"key":"2112_CR210","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/0955-0674(95)80013-1","volume":"7","author":"J Gruenberg","year":"1995","unstructured":"Gruenberg, J. & Maxfield, F. R. Membrane transport in the endocytic pathway. Curr. Opin. Cell Biol. 7, 552\u2013563, (1995).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2112_CR211","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","volume":"148","author":"A Troelnikov","year":"2021","unstructured":"Troelnikov, A. et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J. Allergy Clin. Immunol. 148, 91\u201395 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2112_CR212","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jconrel.2022.09.031","volume":"351","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim, M. et al. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J. Control Release 351, 215\u2013230 (2022).","journal-title":"J. Control Release"},{"key":"2112_CR213","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int Ed. Engl. 49, 6288\u20136308, (2010).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR214","doi-asserted-by":"publisher","DOI":"10.1186\/ar1861","volume":"8","author":"NJ Ganson","year":"2006","unstructured":"Ganson, N. J. et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 8, R12 (2006).","journal-title":"Arthritis Res Ther."},{"key":"2112_CR215","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","volume":"292","author":"ET Dams","year":"2000","unstructured":"Dams, E. T. et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharm. Exp. Ther. 292, 1071\u20131079 (2000).","journal-title":"J. Pharm. Exp. Ther."},{"key":"2112_CR216","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","volume":"88","author":"T Ishida","year":"2003","unstructured":"Ishida, T. et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control Release 88, 35\u201342 (2003).","journal-title":"J. Control Release"},{"key":"2112_CR217","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00766-z","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats. NPJ Vaccines 8, 169 (2023).","journal-title":"NPJ Vaccines"},{"key":"2112_CR218","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","volume":"172","author":"AS Abu Lila","year":"2013","unstructured":"Abu Lila, A. S., Kiwada, H. & Ishida, T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J. Control Release 172, 38\u201347 (2013).","journal-title":"J. Control Release"},{"key":"2112_CR219","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese, F. M. & Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451\u20131458, (2005).","journal-title":"Drug Discov. Today"},{"key":"2112_CR220","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.addr.2006.09.009","volume":"58","author":"VP Torchilin","year":"2006","unstructured":"Torchilin, V. P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532\u20131555 (2006).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR221","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0006-2952(89)90151-2","volume":"38","author":"DA Herold","year":"1989","unstructured":"Herold, D. A., Keil, K. & Bruns, D. E. Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem Pharm. 38, 73\u201376, (1989).","journal-title":"Biochem Pharm."},{"key":"2112_CR222","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymthe.2005.09.014","volume":"13","author":"A Judge","year":"2006","unstructured":"Judge, A., McClintock, K., Phelps, J. R. & Maclachlan, I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol. Ther. 13, 328\u2013337 (2006).","journal-title":"Mol. Ther."},{"key":"2112_CR223","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","volume":"235","author":"S Chen","year":"2016","unstructured":"Chen, S. et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control Release 235, 236\u2013244 (2016).","journal-title":"J. Control Release"},{"key":"2112_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"BL Mui","year":"2013","unstructured":"Mui, B. L. et al. Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol. Ther. Nucleic Acids 2, e139 (2013).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR225","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1016\/j.biomaterials.2011.02.045","volume":"32","author":"H Hatakeyama","year":"2011","unstructured":"Hatakeyama, H. et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 32, 4306\u20134316 (2011).","journal-title":"Biomaterials"},{"key":"2112_CR226","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201903296","volume":"15","author":"V Juang","year":"2019","unstructured":"Juang, V. et al. pH-Responsive PEG-Shedding and Targeting Peptide-Modified Nanoparticles for Dual-Delivery of Irinotecan and microRNA to Enhance Tumor-Specific Therapy. Small 15, e1903296 (2019).","journal-title":"Small"},{"key":"2112_CR227","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","volume":"361","author":"SH El Moukhtari","year":"2023","unstructured":"El Moukhtari, S. H. et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J. Control Release 361, 130\u2013146 (2023).","journal-title":"J. Control Release"},{"key":"2112_CR228","doi-asserted-by":"publisher","first-page":"17549","DOI":"10.1021\/acsnano.1c04456","volume":"15","author":"AA Walters","year":"2021","unstructured":"Walters, A. A. et al. Nanoparticle-Mediated In Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy. ACS Nano 15, 17549\u201317564 (2021).","journal-title":"ACS Nano"},{"key":"2112_CR229","doi-asserted-by":"crossref","unstructured":"Lin, C. et al. Targeting Ligand Independent Tropism of siRNA-LNP by Small Molecules for Directed Therapy of Liver or Myeloid Immune Cells. Adv. Healthc Mater. e2202670, (2023).","DOI":"10.1002\/adhm.202202670"},{"key":"2112_CR230","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1039\/D0BM01609H","volume":"9","author":"R Zhang","year":"2021","unstructured":"Zhang, R. et al. Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver. Biomater. Sci. 9, 1449\u20131463 (2021).","journal-title":"Biomater. Sci."},{"key":"2112_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.43","volume":"5","author":"JB Lee","year":"2016","unstructured":"Lee, J. B. et al. A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle\/siRNA System Inhibits Androgen Receptor Expression In Vivo. Mol. Ther. Nucleic Acids 5, e348 (2016).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR232","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","volume":"9","author":"S Ramishetti","year":"2015","unstructured":"Ramishetti, S. et al. Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano 9, 6706\u20136716 (2015).","journal-title":"ACS Nano"},{"key":"2112_CR233","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","volume":"331","author":"MA Younis","year":"2021","unstructured":"Younis, M. A. et al. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. J. Control Release 331, 335\u2013349 (2021).","journal-title":"J. Control Release"},{"key":"2112_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122341","volume":"302","author":"V Passos Gibson","year":"2023","unstructured":"Passos Gibson, V. et al. Hyaluronan decorated layer-by-layer assembled lipid nanoparticles for miR-181a delivery in glioblastoma treatment. Biomaterials 302, 122341 (2023).","journal-title":"Biomaterials"},{"key":"2112_CR235","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7162","volume":"8","author":"X Bai","year":"2022","unstructured":"Bai, X. et al. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci. Adv. 8, eabn7162 (2022).","journal-title":"Sci. Adv."},{"key":"2112_CR236","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s00417-020-04797-3","volume":"258","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles. Graefes Arch. Clin. Exp. Ophthalmol. 258, 2407\u20132418 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"2112_CR237","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2015.12.016","volume":"223","author":"K H\u00f6rmann","year":"2016","unstructured":"H\u00f6rmann, K. & Zimmer, A. Drug delivery and drug targeting with parenteral lipid nanoemulsions - A review. J. Control Release 223, 85\u201398 (2016).","journal-title":"J. Control Release"},{"key":"2112_CR238","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","volume":"16","author":"Y Xu","year":"2022","unstructured":"Xu, Y. et al. Surface Modification of Lipid-Based Nanoparticles. ACS Nano 16, 7168\u20137196 (2022).","journal-title":"ACS Nano"},{"key":"2112_CR239","first-page":"885","volume":"11","author":"IF Kretzer","year":"2016","unstructured":"Kretzer, I. F. et al. Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice. Int J. Nanomed. 11, 885\u2013904, (2016).","journal-title":"Int J. Nanomed."},{"key":"2112_CR240","first-page":"3141","volume":"8","author":"SP Jiang","year":"2013","unstructured":"Jiang, S. P. et al. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. Int J. Nanomed. 8, 3141\u20133150 (2013).","journal-title":"Int J. Nanomed."},{"key":"2112_CR241","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1016\/j.biomaterials.2010.01.006","volume":"31","author":"MM Kaneda","year":"2010","unstructured":"Kaneda, M. M. et al. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 31, 3079\u20133086 (2010).","journal-title":"Biomaterials"},{"key":"2112_CR242","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ijpharm.2016.07.067","volume":"511","author":"S Gehrmann","year":"2016","unstructured":"Gehrmann, S. & Bunjes, H. Preparation of lipid nanoemulsions by premix membrane emulsification with disposable materials. Int J. Pharm. 511, 741\u2013744 (2016).","journal-title":"Int J. Pharm."},{"key":"2112_CR243","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jconrel.2024.08.021","volume":"374","author":"N Baumann","year":"2024","unstructured":"Baumann, N., Baumgarten, J., Kunick, C. & Bunjes, H. Prolonged release from lipid nanoemulsions by modification of drug lipophilicity. J Control Release 374, 478\u2013488 (2024).","journal-title":"J Control Release"},{"key":"2112_CR244","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"N Naseri","year":"2015","unstructured":"Naseri, N., Valizadeh, H. & Zakeri-Milani, P. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. Adv. Pharm. Bull. 5, 305\u2013313 (2015).","journal-title":"Adv. Pharm. Bull."},{"key":"2112_CR245","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos, C., Battaglini, M. & Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control Release 264, 306\u2013332 (2017).","journal-title":"J. Control Release"},{"key":"2112_CR246","doi-asserted-by":"publisher","first-page":"129840","DOI":"10.1016\/j.foodchem.2021.129840","volume":"358","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Nanoencapsulation of lutein within lipid-based delivery systems: Characterization and comparison of zein peptide stabilized nano-emulsion, solid lipid nanoparticle, and nano-structured lipid carrier. Food Chem. 358, 129840 (2021).","journal-title":"Food Chem."},{"key":"2112_CR247","doi-asserted-by":"publisher","first-page":"132934","DOI":"10.1016\/j.foodchem.2022.132934","volume":"387","author":"A Shirvani","year":"2022","unstructured":"Shirvani, A. et al. Fabrication of edible solid lipid nanoparticle from beeswax\/propolis wax by spontaneous emulsification: Optimization, characterization and stability. Food Chem. 387, 132934 (2022).","journal-title":"Food Chem."},{"key":"2112_CR248","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejpb.2008.09.015","volume":"71","author":"A del Pozo-Rodr\u00edguez","year":"2009","unstructured":"del Pozo-Rodr\u00edguez, A., Solin\u00eds, M. A., Gasc\u00f3n, A. R. & Pedraz, J. L. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur. J. Pharm. Biopharm. 71, 181\u2013189 (2009).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2112_CR249","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.colsurfb.2010.04.005","volume":"79","author":"T Wang","year":"2010","unstructured":"Wang, T. et al. Solvent injection-lyophilization of tert-butyl alcohol\/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles. Colloids Surf. B Biointerf. 79, 254\u2013261 (2010).","journal-title":"Colloids Surf. B Biointerf."},{"key":"2112_CR250","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejpb.2016.10.010","volume":"110","author":"G Sandri","year":"2017","unstructured":"Sandri, G. et al. Chitosan-coupled solid lipid nanoparticles: Tuning nanostructure and mucoadhesion. Eur. J. Pharm. Biopharm. 110, 13\u201318 (2017).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2112_CR251","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2020.06.004","volume":"325","author":"Z Huang","year":"2020","unstructured":"Huang, Z. et al. Relationship between particle size and lung retention time of intact solid lipid nanoparticle suspensions after pulmonary delivery. J. Control Release 325, 206\u2013222 (2020).","journal-title":"J. Control Release"},{"key":"2112_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.117180","volume":"252","author":"JM Mohamed","year":"2021","unstructured":"Mohamed, J. M. et al. Pectin co-functionalized dual layered solid lipid nanoparticle made by soluble curcumin for the targeted potential treatment of colorectal cancer. Carbohydr. Polym. 252, 117180 (2021).","journal-title":"Carbohydr. Polym."},{"key":"2112_CR253","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2014.06.004","volume":"188","author":"Y Rosiaux","year":"2014","unstructured":"Rosiaux, Y., Jannin, V., Hughes, S. & Marchaud, D. Solid lipid excipients - matrix agents for sustained drug delivery. J. Control Release 188, 18\u201330 (2014).","journal-title":"J. Control Release"},{"key":"2112_CR254","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.foodres.2017.12.036","volume":"105","author":"B Mehrad","year":"2018","unstructured":"Mehrad, B. et al. Enhancing the physicochemical stability of \u03b2-carotene solid lipid nanoparticle (SLNP) using whey protein isolate. Food Res Int. 105, 962\u2013969 (2018).","journal-title":"Food Res Int."},{"key":"2112_CR255","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","volume":"11","author":"CP Costa","year":"2021","unstructured":"Costa, C. P., Moreira, J. N., Sousa Lobo, J. M. & Silva, A. C. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm. Sin. B 11, 925\u2013940 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"2112_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodres.2022.111119","volume":"155","author":"MG da Silva","year":"2022","unstructured":"da Silva, M. G. et al. Developed and characterization of nanostructured lipid carriers containing food-grade interesterified lipid phase for food application. Food Res. Int.155, 111119 (2022).","journal-title":"Food Res. Int"},{"key":"2112_CR257","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017019047","volume":"34","author":"G Sharma","year":"2017","unstructured":"Sharma, G. et al. Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications. Crit. Rev. Ther. Drug Carr. Syst. 34, 355\u2013386 (2017).","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"2112_CR258","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1080\/10408398.2020.1792409","volume":"61","author":"C Dima","year":"2021","unstructured":"Dima, C., Assadpour, E., Dima, S. & Jafari, S. M. Nutraceutical nanodelivery; an insight into the bioaccessibility\/bioavailability of different bioactive compounds loaded within nanocarriers. Crit. Rev. Food Sci. Nutr. 61, 3031\u20133065 (2021).","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"2112_CR259","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","volume":"54","author":"RH M\u00fcller","year":"2002","unstructured":"M\u00fcller, R. H., Radtke, M. & Wissing, S. A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54, S131\u2013S155 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR260","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1080\/10837450.2020.1759630","volume":"25","author":"E Oner","year":"2020","unstructured":"Oner, E., Kotmakci, M. & Kantarci, A. G. A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability. Pharm. Dev. Technol. 25, 936\u2013948 (2020).","journal-title":"Pharm. Dev. Technol."},{"key":"2112_CR261","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1021\/nl502275s","volume":"14","author":"A Rajala","year":"2014","unstructured":"Rajala, A. et al. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo. Nano Lett. 14, 5257\u20135263 (2014).","journal-title":"Nano Lett."},{"key":"2112_CR262","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-chembioeng-101121-070232","volume":"14","author":"S Urandur","year":"2023","unstructured":"Urandur, S. & Sullivan, M. O. Peptide-Based Vectors: A Biomolecular Engineering Strategy for Gene Delivery. Annu Rev. Chem. Biomol. Eng. 14, 243\u2013264 (2023).","journal-title":"Annu Rev. Chem. Biomol. Eng."},{"key":"2112_CR263","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","volume":"55","author":"AD Frankel","year":"1988","unstructured":"Frankel, A. D. & Pabo, C. O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189\u20131193, (1988).","journal-title":"Cell"},{"key":"2112_CR264","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti, G., Brambilla, L. & Rossi, D. Cell-Penetrating Peptides: From Basic Research to Clinics. Trends Pharm. Sci. 38, 406\u2013424 (2017).","journal-title":"Trends Pharm. Sci."},{"key":"2112_CR265","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.addr.2016.06.008","volume":"106","author":"T Lehto","year":"2016","unstructured":"Lehto, T., Ezzat, K., Wood, M. J. A. & El Andaloussi, S. Peptides for nucleic acid delivery. Adv. Drug Deliv. Rev. 106, 172\u2013182 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR266","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.3390\/nano12224076","volume":"12","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Liu, Z., Ma, H. & Cao, M. Application of Peptides in Construction of Nonviral Vectors for Gene Delivery. Nanomaterials (Basel) 12, 4076 (2022).","journal-title":"Nanomaterials (Basel)"},{"key":"2112_CR267","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.1002\/anie.200906820","volume":"49","author":"M Kwak","year":"2010","unstructured":"Kwak, M. & Herrmann, A. Nucleic acid\/organic polymer hybrid materials: synthesis, superstructures, and applications. Angew. Chem. Int Ed. Engl. 49, 8574\u20138587 (2010).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR268","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/tcr.201600085","volume":"17","author":"P Dhasaiyan","year":"2017","unstructured":"Dhasaiyan, P. & Prasad, B. L. V. Self-Assembly of Bolaamphiphilic Molecules. Chem. Rec. 17, 597\u2013610 (2017).","journal-title":"Chem. Rec."},{"key":"2112_CR269","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jconrel.2020.11.028","volume":"330","author":"MM Khan","year":"2021","unstructured":"Khan, M. M., Filipczak, N. & Torchilin, V. P. Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer. J. Control Release 330, 1220\u20131228 (2021).","journal-title":"J. Control Release"},{"key":"2112_CR270","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1021\/ja0482536","volume":"126","author":"JB Rothbard","year":"2004","unstructured":"Rothbard, J. B. et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126, 9506\u20139507 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR271","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1042\/BC20070116","volume":"100","author":"MC Morris","year":"2008","unstructured":"Morris, M. C., Deshayes, S., Heitz, F. & Divita, G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol. Cell 100, 201\u2013217, (2008).","journal-title":"Biol. Cell"},{"key":"2112_CR272","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1042\/BJ20050401","volume":"390","author":"C De Coupade","year":"2005","unstructured":"De Coupade, C. et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J. 390, 407\u2013418 (2005).","journal-title":"Biochem J."},{"key":"2112_CR273","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jconrel.2021.12.034","volume":"342","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy. J. Control Release 342, 66\u201380 (2022).","journal-title":"J. Control Release"},{"key":"2112_CR274","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s43556-021-00058-9","volume":"2","author":"R Zhang","year":"2021","unstructured":"Zhang, R. et al. Cholesterol modified DP7 and pantothenic acid induce dendritic cell homing to enhance the efficacy of dendritic cell vaccines. Mol. Biomed. 2, 37 (2021).","journal-title":"Mol. Biomed."},{"key":"2112_CR275","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1111\/cas.14903","volume":"112","author":"B Zhao","year":"2021","unstructured":"Zhao, B. et al. Sustained and targeted delivery of siRNA\/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy. Cancer Sci. 112, 2481\u20132492 (2021).","journal-title":"Cancer Sci."},{"key":"2112_CR276","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1021\/acs.molpharmaceut.0c01253","volume":"18","author":"R Zhang","year":"2021","unstructured":"Zhang, R. et al. A Peptide-Based Small RNA Delivery System to Suppress Tumor Growth by Remodeling the Tumor Microenvironment. Mol. Pharm. 18, 1431\u20131443 (2021).","journal-title":"Mol. Pharm."},{"key":"2112_CR277","volume":"10","author":"M Liu","year":"2023","unstructured":"Liu, M. et al. In Situ Cocktail Nanovaccine for Cancer Immunotherapy. Adv. Sci. (Weinh.) 10, e2207697 (2023).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2112_CR278","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nm996","volume":"10","author":"JS Wadia","year":"2004","unstructured":"Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med 10, 310\u2013315, (2004).","journal-title":"Nat. Med"},{"key":"2112_CR279","doi-asserted-by":"publisher","first-page":"20785","DOI":"10.1039\/C4CP02211D","volume":"16","author":"D Sun","year":"2014","unstructured":"Sun, D., Forsman, J., Lund, M. & Woodward, C. E. Effect of arginine-rich cell penetrating peptides on membrane pore formation and life-times: a molecular simulation study. Phys. Chem. Chem. Phys. 16, 20785\u201320795, (2014).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"2112_CR280","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2017.02.003","volume":"7","author":"L P\u00e4rnaste","year":"2017","unstructured":"P\u00e4rnaste, L. et al. The Formation of Nanoparticles between Small Interfering RNA and Amphipathic Cell-Penetrating Peptides. Mol. Ther. Nucleic Acids 7, 1\u201310 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR281","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/nar\/gkg385","volume":"31","author":"F Simeoni","year":"2003","unstructured":"Simeoni, F., Morris, M. C., Heitz, F. & Divita, G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31, 2717\u20132724, (2003).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR282","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1093\/nar\/gkp451","volume":"37","author":"L Crombez","year":"2009","unstructured":"Crombez, L. et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37, 4559\u20134569 (2009).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR283","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nbt.1541","volume":"27","author":"A Eguchi","year":"2009","unstructured":"Eguchi, A. et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat. Biotechnol. 27, 567\u2013571 (2009).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR284","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.4161\/cbt.8.23.10271","volume":"8","author":"H Michiue","year":"2009","unstructured":"Michiue, H., Eguchi, A., Scadeng, M. & Dowdy, S. F. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther. 8, 2306\u20132313, (2009).","journal-title":"Cancer Biol. Ther."},{"key":"2112_CR285","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nbt0998-857","volume":"16","author":"M Pooga","year":"1998","unstructured":"Pooga, M. et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16, 857\u2013861 (1998).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR286","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/0008-5472.CAN-08-2932","volume":"69","author":"BN Taylor","year":"2009","unstructured":"Taylor, B. N. et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 69, 537\u2013546 (2009).","journal-title":"Cancer Res."},{"key":"2112_CR287","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1021\/mp200481g","volume":"9","author":"RH Mo","year":"2012","unstructured":"Mo, R. H., Zaro, J. L. & Shen, W. C. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol. Pharm. 9, 299\u2013309 (2012).","journal-title":"Mol. Pharm."},{"key":"2112_CR288","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1006\/excr.2001.5316","volume":"269","author":"A Elmquist","year":"2001","unstructured":"Elmquist, A., Lindgren, M., Bartfai, T. & Langel, U. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp. Cell Res 269, 237\u2013244 (2001).","journal-title":"Exp. Cell Res"},{"key":"2112_CR289","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.mt.6300346","volume":"16","author":"HJ Johansson","year":"2008","unstructured":"Johansson, H. J. et al. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol. Ther. 16, 115\u2013123 (2008).","journal-title":"Mol. Ther."},{"key":"2112_CR290","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbrc.2006.07.065","volume":"348","author":"M Magzoub","year":"2006","unstructured":"Magzoub, M. et al. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys. Res Commun. 348, 379\u2013385 (2006).","journal-title":"Biochem Biophys. Res Commun."},{"key":"2112_CR291","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/mt.2008.215","volume":"17","author":"L Crombez","year":"2009","unstructured":"Crombez, L. et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol. Ther. 17, 95\u2013103 (2009).","journal-title":"Mol. Ther."},{"key":"2112_CR292","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/bip.10585","volume":"76","author":"J Fern\u00e1ndez-Carneado","year":"2004","unstructured":"Fern\u00e1ndez-Carneado, J., Kogan, M. J., Pujals, S. & Giralt, E. Amphipathic peptides and drug delivery. Biopolymers 76, 196\u2013203 (2004).","journal-title":"Biopolymers"},{"key":"2112_CR293","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.bmcl.2019.05.044","volume":"29","author":"SI Wada","year":"2019","unstructured":"Wada, S. I. et al. Influence of lysine residue in amphipathic helical peptides on targeted delivery of RNA into cancer cells. Bioorg. Med Chem. Lett. 29, 1934\u20131937 (2019).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"2112_CR294","doi-asserted-by":"publisher","first-page":"e202100728","DOI":"10.1002\/cbdv.202100728","volume":"19","author":"SI Wada","year":"2022","unstructured":"Wada, S. I., Shibaike, A., Hayashi, J. & Urata, H. Influence of Aib-Containing Amphipathic Helical Chain Length in MAP(Aib)-cRGD as Carrier for siRNA Delivery. Chem. Biodivers. 19, e202100728 (2022).","journal-title":"Chem. Biodivers."},{"key":"2112_CR295","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijpharm.2016.05.030","volume":"509","author":"K Konate","year":"2016","unstructured":"Konate, K. et al. Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptide. Int J. Pharm. 509, 71\u201384 (2016).","journal-title":"Int J. Pharm."},{"key":"2112_CR296","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1046\/j.1432-1033.2002.03119.x","volume":"269","author":"G Kragol","year":"2002","unstructured":"Kragol, G. et al. Identification of crucial residues for the antibacterial activity of the proline-rich peptide, pyrrhocoricin. Eur. J. Biochem 269, 4226\u20134237 (2002).","journal-title":"Eur. J. Biochem"},{"key":"2112_CR297","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00018-002-8493-8","volume":"59","author":"L Otvos Jr","year":"2002","unstructured":"Otvos, L. Jr The short proline-rich antibacterial peptide family. Cell Mol. Life Sci. 59, 1138\u20131150 (2002).","journal-title":"Cell Mol. Life Sci."},{"key":"2112_CR298","doi-asserted-by":"publisher","first-page":"14150","DOI":"10.1021\/bi026661l","volume":"41","author":"K Sadler","year":"2002","unstructured":"Sadler, K. et al. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41, 14150\u201314157 (2002).","journal-title":"Biochemistry"},{"key":"2112_CR299","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2174\/09298665113206660110","volume":"21","author":"S Stalmans","year":"2014","unstructured":"Stalmans, S. et al. Blood-brain barrier transport of short proline-rich antimicrobial peptides. Protein Pept. Lett. 21, 399\u2013406 (2014).","journal-title":"Protein Pept. Lett."},{"key":"2112_CR300","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.106054","volume":"168","author":"P Fr\u00f8slev","year":"2022","unstructured":"Fr\u00f8slev, P. et al. Highly cationic cell-penetrating peptides affect the barrier integrity and facilitates mannitol permeation in a human stem cell-based blood-brain barrier model. Eur. J. Pharm. Sci. 168, 106054 (2022).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2112_CR301","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1161\/01.CIR.0000124067.35915.E0","volume":"109","author":"J Wu","year":"2004","unstructured":"Wu, J. et al. PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2. Circulation 109, 1660\u20131667 (2004).","journal-title":"Circulation"},{"key":"2112_CR302","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3892\/or.2012.1911","volume":"28","author":"W Tian","year":"2012","unstructured":"Tian, W. et al. Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39. Oncol. Rep. 28, 1362\u20131368 (2012).","journal-title":"Oncol. Rep."},{"key":"2112_CR303","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fbioe.2020.00162","volume":"8","author":"LK Mueller","year":"2020","unstructured":"Mueller, L. K., Baumruck, A. C., Zhdanova, H. & Tietze, A. A. Challenges and Perspectives in Chemical Synthesis of Highly Hydrophobic Peptides. Front Bioeng. Biotechnol. 8, 162 (2020).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2112_CR304","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1021\/acs.bioconjchem.6b00535","volume":"28","author":"S Schmidt","year":"2017","unstructured":"Schmidt, S. et al. Identification of Short Hydrophobic Cell-Penetrating Peptides for Cytosolic Peptide Delivery by Rational Design. Bioconjug Chem. 28, 382\u2013389 (2017).","journal-title":"Bioconjug Chem."},{"key":"2112_CR305","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1016\/S0968-0896(02)00340-1","volume":"10","author":"C Gao","year":"2002","unstructured":"Gao, C. et al. A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorg. Med Chem. 10, 4057\u20134065 (2002).","journal-title":"Bioorg. Med Chem."},{"key":"2112_CR306","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1039\/D0BM01755H","volume":"9","author":"K Desale","year":"2021","unstructured":"Desale, K., Kuche, K. & Jain, S. Cell-penetrating peptides (CPPs): an overview of applications for improving the potential of nanotherapeutics. Biomater. Sci. 9, 1153\u20131188 (2021).","journal-title":"Biomater. Sci."},{"key":"2112_CR307","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1074\/jbc.M509813200","volume":"281","author":"M Rhee","year":"2006","unstructured":"Rhee, M. & Davis, P. Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J. Biol. Chem. 281, 1233\u20131240 (2006).","journal-title":"J. Biol. Chem."},{"key":"2112_CR308","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2013.11.020","volume":"174","author":"F Wang","year":"2014","unstructured":"Wang, F. et al. Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J. Control Release 174, 126\u2013136 (2014).","journal-title":"J. Control Release"},{"key":"2112_CR309","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jconrel.2008.11.025","volume":"134","author":"M M\u00e4e","year":"2009","unstructured":"M\u00e4e, M. et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control Release 134, 221\u2013227 (2009).","journal-title":"J. Control Release"},{"key":"2112_CR310","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/anie.200502113","volume":"45","author":"R Haag","year":"2006","unstructured":"Haag, R. & Kratz, F. Polymer therapeutics: concepts and applications. Angew. Chem. Int Ed. Engl. 45, 1198\u20131215 (2006).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR311","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","volume":"92","author":"T Hamaguchi","year":"2005","unstructured":"Hamaguchi, T. et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240\u20131246 (2005).","journal-title":"Br. J. Cancer"},{"key":"2112_CR312","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.drudis.2013.06.014","volume":"18","author":"A Aied","year":"2013","unstructured":"Aied, A., Greiser, U., Pandit, A. & Wang, W. Polymer gene delivery: overcoming the obstacles. Drug Discov. Today 18, 1090\u20131098, (2013).","journal-title":"Drug Discov. Today"},{"key":"2112_CR313","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1039\/c2cs35146c","volume":"41","author":"M J\u00e4ger","year":"2012","unstructured":"J\u00e4ger, M. et al. Branched and linear poly(ethylene imine)-based conjugates: synthetic modification, characterization, and application. Chem. Soc. Rev. 41, 4755\u20134767 (2012).","journal-title":"Chem. Soc. Rev."},{"key":"2112_CR314","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.biomaterials.2011.03.016","volume":"32","author":"D Dey","year":"2011","unstructured":"Dey, D. et al. Efficient gene delivery of primary human cells using peptide linked polyethylenimine polymer hybrid. Biomaterials 32, 4647\u20134658 (2011).","journal-title":"Biomaterials"},{"key":"2112_CR315","doi-asserted-by":"publisher","first-page":"114460","DOI":"10.1016\/j.addr.2022.114460","volume":"190","author":"O Gueta","year":"2022","unstructured":"Gueta, O. & Amiram, M. Expanding the chemical repertoire of protein-based polymers for drug-delivery applications. Adv. Drug Deliv. Rev. 190, 114460 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR316","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1021\/jacs.2c12517","volume":"145","author":"F Sbordone","year":"2023","unstructured":"Sbordone, F. et al. Embedding Peptides into Synthetic Polymers: Radical Ring-Opening Copolymerization of Cyclic Peptides. J. Am. Chem. Soc. 145, 6221\u20136229 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR317","doi-asserted-by":"publisher","first-page":"e2105063","DOI":"10.1002\/adma.202105063","volume":"34","author":"K Jung","year":"2022","unstructured":"Jung, K., Corrigan, N., Wong, E. H. H. & Boyer, C. Bioactive Synthetic Polymers. Adv. Mater. 34, e2105063 (2022).","journal-title":"Adv. Mater."},{"key":"2112_CR318","doi-asserted-by":"publisher","first-page":"e2001060","DOI":"10.1002\/smtd.202001060","volume":"5","author":"S Zhu","year":"2021","unstructured":"Zhu, S. et al. Recent Advances in Patterning Natural Polymers: From Nanofabrication Techniques to Applications. Small Methods 5, e2001060 (2021).","journal-title":"Small Methods"},{"key":"2112_CR319","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Synthesis of Polymer-Lipid Nanoparticles by Microfluidic Focusing for siRNA Delivery. Molecules. 21, (2016).","DOI":"10.3390\/molecules21101314"},{"key":"2112_CR320","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ymthe.2005.02.010","volume":"11","author":"SM Moghimi","year":"2005","unstructured":"Moghimi, S. M. et al. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer\/therapy. Mol. Ther. 11, 990\u2013995 (2005).","journal-title":"Mol. Ther."},{"key":"2112_CR321","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nmat3209","volume":"11","author":"E Mastrobattista","year":"2011","unstructured":"Mastrobattista, E. & Hennink, W. E. Polymers for gene delivery: Charged for success. Nat. Mater. 11, 10\u201312, (2011).","journal-title":"Nat. Mater."},{"key":"2112_CR322","doi-asserted-by":"publisher","first-page":"8173","DOI":"10.1002\/anie.201914751","volume":"59","author":"HS Min","year":"2020","unstructured":"Min, H. S. et al. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood-Brain Barrier with a Glucose-Coated Polymeric Nanocarrier. Angew. Chem. Int Ed. Engl. 59, 8173\u20138180 (2020).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR323","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1021\/acsabm.1c00334","volume":"4","author":"D Ara\u00fajo","year":"2021","unstructured":"Ara\u00fajo, D. et al. Polyamide Microsized Particulate Polyplex Carriers for the 2\u2019-OMethylRNA EFG1 Antisense Oligonucleotide. ACS Appl. Bio. Mater. 4, 4607\u20134617 (2021).","journal-title":"ACS Appl. Bio. Mater."},{"key":"2112_CR324","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.apsb.2023.09.001","volume":"14","author":"S Guo","year":"2024","unstructured":"Guo, S. et al. pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy. Acta Pharm. Sin. B 14, 781\u2013794 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2112_CR325","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jconrel.2024.02.018","volume":"367","author":"AS Ansari","year":"2024","unstructured":"Ansari, A. S. et al. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models. J. Control Release 367, 821\u2013836 (2024).","journal-title":"J. Control Release"},{"key":"2112_CR326","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202400228","volume":"36","author":"S Guo","year":"2024","unstructured":"Guo, S. et al. Spatiotemporal-Controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy. Adv. Mater. 36, e2400228 (2024).","journal-title":"Adv. Mater."},{"key":"2112_CR327","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/acs.nanolett.3c04507","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy. Nano Lett. 24, 1376\u20131384 (2024).","journal-title":"Nano Lett."},{"key":"2112_CR328","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.actbio.2022.11.016","volume":"155","author":"Y Ma","year":"2023","unstructured":"Ma, Y. et al. A miRNA-based gene therapy nanodrug synergistically enhances pro-inflammatory antitumor immunity against melanoma. Acta Biomater. 155, 538\u2013553 (2023).","journal-title":"Acta Biomater."},{"key":"2112_CR329","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1021\/jf062919t","volume":"55","author":"SM Rutherfurd","year":"2007","unstructured":"Rutherfurd, S. M., Rutherfurd-Markwick, K. J. & Moughan, P. J. Available (ileal digestible reactive) lysine in selected pet foods. J. Agric Food Chem. 55, 3517\u20133522, (2007).","journal-title":"J. Agric Food Chem."},{"key":"2112_CR330","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jmmm.2016.11.014","volume":"427","author":"I Khmara","year":"2017","unstructured":"Khmara, I. et al. Preparation of poly-L-lysine functionalized magnetic nanoparticles and their influence on viability of cancer cells. J. Magn. Magn. Mater. 427, 114\u2013121 (2017).","journal-title":"J. Magn. Magn. Mater."},{"key":"2112_CR331","doi-asserted-by":"publisher","first-page":"108147","DOI":"10.1016\/j.bioelechem.2022.108147","volume":"146","author":"DV Estrada-Osorio","year":"2022","unstructured":"Estrada-Osorio, D. V. et al. Poly-L-lysine-modified with ferrocene to obtain a redox polymer for mediated glucose biosensor application. Bioelectrochemistry 146, 108147 (2022).","journal-title":"Bioelectrochemistry"},{"key":"2112_CR332","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jconrel.2022.03.034","volume":"345","author":"S Yang","year":"2022","unstructured":"Yang, S. et al. Drug-free neutrally charged polypeptide nanoparticles as anticancer agents. J. Control Release 345, 464\u2013474 (2022).","journal-title":"J. Control Release"},{"key":"2112_CR333","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1021\/nn300942b","volume":"6","author":"RJ Christie","year":"2012","unstructured":"Christie, R. J. et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6, 5174\u20135189 (2012).","journal-title":"ACS Nano"},{"key":"2112_CR334","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bmc.2006.09.033","volume":"15","author":"M Yamagata","year":"2007","unstructured":"Yamagata, M. et al. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorg. Med Chem. 15, 526\u2013532 (2007).","journal-title":"Bioorg. Med Chem."},{"key":"2112_CR335","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jconrel.2007.10.022","volume":"126","author":"Y Inoue","year":"2008","unstructured":"Inoue, Y. et al. Efficient delivery of siRNA using dendritic poly(L-lysine) for loss-of-function analysis. J. Control Release 126, 59\u201366 (2008).","journal-title":"J. Control Release"},{"key":"2112_CR336","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1016\/j.biomaterials.2014.01.040","volume":"35","author":"T Liu","year":"2014","unstructured":"Liu, T. et al. Star-shaped cyclodextrin-poly(l-lysine) derivative co-delivering docetaxel and MMP-9 siRNA plasmid in cancer therapy. Biomaterials 35, 3865\u20133872 (2014).","journal-title":"Biomaterials"},{"key":"2112_CR337","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0147-6513(87)90062-5","volume":"14","author":"S Hatakeyama","year":"1987","unstructured":"Hatakeyama, S. & Yasuno, M. Chronic effects of Cd on the reproduction of the guppy (Poecilia reticulata) through Cd-accumulated midge larvae (Chironomus yoshimatsui). Ecotoxicol. Environ. Saf. 14, 191\u2013207 (1987).","journal-title":"Ecotoxicol. Environ. Saf."},{"key":"2112_CR338","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1517\/17425247.2013.840286","volume":"10","author":"R Molinaro","year":"2013","unstructured":"Molinaro, R. et al. Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin. Drug Deliv. 10, 1653\u20131668 (2013).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2112_CR339","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","volume":"362","author":"J Casper","year":"2023","unstructured":"Casper, J. et al. Polyethylenimine (PEI) in gene therapy: Current status and clinical applications. J. Control Release 362, 667\u2013691 (2023).","journal-title":"J. Control Release"},{"key":"2112_CR340","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif, O. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297\u20137301 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR341","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/ijms17040555","volume":"17","author":"CN Lungu","year":"2016","unstructured":"Lungu, C. N., Diudea, M. V., Putz, M. V. & Grudzi\u0144ski, I. P. Linear and Branched PEIs (Polyethylenimines) and Their Property Space. Int J. Mol. Sci. 17, 555 (2016).","journal-title":"Int J. Mol. Sci."},{"key":"2112_CR342","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.biomaterials.2010.10.044","volume":"32","author":"J Dai","year":"2011","unstructured":"Dai, J. et al. Polyethylenimine-grafted copolymer of poly(l-lysine) and poly(ethylene glycol) for gene delivery. Biomaterials 32, 1694\u20131705 (2011).","journal-title":"Biomaterials"},{"key":"2112_CR343","doi-asserted-by":"publisher","first-page":"e2307062","DOI":"10.1002\/smll.202307062","volume":"20","author":"F Qiao","year":"2024","unstructured":"Qiao, F., Zou, Y., Bie, B. & Lv, Y. Dual siRNA-Loaded Cell Membrane Functionalized Matrix Facilitates Bone Regeneration with Angiogenesis and Neurogenesis. Small 20, e2307062 (2024).","journal-title":"Small"},{"key":"2112_CR344","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/mt.2014.24","volume":"22","author":"SM Francis","year":"2014","unstructured":"Francis, S. M. et al. SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide. Mol. Ther. 22, 1643\u20131652 (2014).","journal-title":"Mol. Ther."},{"key":"2112_CR345","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/mt.2012.94","volume":"20","author":"CA Taylor","year":"2012","unstructured":"Taylor, C. A. et al. Modulation of eIF5A expression using SNS01 nanoparticles inhibits NF-\u03baB activity and tumor growth in murine models of multiple myeloma. Mol. Ther. 20, 1305\u20131314 (2012).","journal-title":"Mol. Ther."},{"key":"2112_CR346","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801359","volume":"8","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Li, Y., Keskin, D. & Shi, L. Poly(\u03b2-Amino Esters): Synthesis, Formulations, and Their Biomedical Applications. Adv. Health Mater. 8, e1801359 (2019).","journal-title":"Adv. Health Mater."},{"key":"2112_CR347","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2023.01.002","volume":"354","author":"J Wei","year":"2023","unstructured":"Wei, J. et al. Recent progress and applications of poly(beta amino esters)-based biomaterials. J. Control Release 354, 337\u2013353 (2023).","journal-title":"J. Control Release"},{"key":"2112_CR348","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.omtn.2023.04.019","volume":"32","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Poly(\u03b2-amino ester)s-based nanovehicles: Structural regulation and gene delivery. Mol. Ther. Nucleic Acids 32, 568\u2013581 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR349","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1021\/acs.nanolett.2c00540","volume":"22","author":"DY Hou","year":"2022","unstructured":"Hou, D. Y. et al. A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer. Nano Lett. 22, 3983\u20133992 (2022).","journal-title":"Nano Lett."},{"key":"2112_CR350","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1021\/acsbiomaterials.0c00271","volume":"6","author":"D Routkevitch","year":"2020","unstructured":"Routkevitch, D. et al. Efficiency of Cytosolic Delivery with Poly(\u03b2-amino ester) Nanoparticles is Dependent on the Effective pK(a) of the Polymer. ACS Biomater. Sci. Eng. 6, 3411\u20133421 (2020).","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2112_CR351","first-page":"75","volume":"29","author":"Y Sugie","year":"1989","unstructured":"Sugie, Y. et al. [A case of systemic lupus erythematosus associated with lateral medullary syndrome and unilateral internuclear ophthalmoplegia]. Rinsho Shinkeigaku 29, 75\u201379 (1989).","journal-title":"Rinsho Shinkeigaku"},{"key":"2112_CR352","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1021\/ar7002336","volume":"41","author":"JJ Green","year":"2008","unstructured":"Green, J. J., Langer, R. & Anderson, D. G. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. 41, 749\u2013759, (2008).","journal-title":"Acc. Chem. Res."},{"key":"2112_CR353","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1021\/acs.biomac.2c00137","volume":"23","author":"Q Chen","year":"2022","unstructured":"Chen, Q. et al. Poly(beta-amino ester)-Based Nanoparticles Enable Nonviral Delivery of Base Editors for Targeted Tumor Gene Editing. Biomacromolecules 23, 2116\u20132125 (2022).","journal-title":"Biomacromolecules"},{"key":"2112_CR354","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1039\/C4TB02144D","volume":"3","author":"ZY Qiao","year":"2015","unstructured":"Qiao, Z. Y. et al. Self-assembly of cytotoxic peptide conjugated poly(\u03b2-amino ester)s for synergistic cancer chemotherapy. J. Mater. Chem. B 3, 2943\u20132953 (2015).","journal-title":"J. Mater. Chem. B"},{"key":"2112_CR355","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo6406","volume":"8","author":"HJ Vaughan","year":"2022","unstructured":"Vaughan, H. J. et al. Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma. Sci. Adv. 8, eabo6406 (2022).","journal-title":"Sci. Adv."},{"key":"2112_CR356","doi-asserted-by":"publisher","first-page":"7913","DOI":"10.1021\/acsami.0c19955","volume":"13","author":"KR Rhodes","year":"2021","unstructured":"Rhodes, K. R. et al. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma. ACS Appl. Mater. Interf. 13, 7913\u20137923 (2021).","journal-title":"ACS Appl. Mater. Interf."},{"key":"2112_CR357","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1021\/nn500704t","volume":"8","author":"KL Kozielski","year":"2014","unstructured":"Kozielski, K. L., Tzeng, S. Y., De Mendoza, B. A. & Green, J. J. Bioreducible cationic polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain cancer cells. ACS Nano 8, 3232\u20133241, (2014).","journal-title":"ACS Nano"},{"key":"2112_CR358","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.1016\/j.biomaterials.2012.07.036","volume":"33","author":"SY Tzeng","year":"2012","unstructured":"Tzeng, S. Y., Hung, B. P., Grayson, W. L. & Green, J. J. Cystamine-terminated poly(beta-amino ester)s for siRNA delivery to human mesenchymal stem cells and enhancement of osteogenic differentiation. Biomaterials 33, 8142\u20138151, (2012).","journal-title":"Biomaterials"},{"key":"2112_CR359","doi-asserted-by":"publisher","first-page":"199","DOI":"10.18388\/abp.2001_5127","volume":"48","author":"B Klajnert","year":"2001","unstructured":"Klajnert, B. & Bryszewska, M. Dendrimers: properties and applications. Acta Biochim Pol. 48, 199\u2013208 (2001).","journal-title":"Acta Biochim Pol."},{"key":"2112_CR360","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","volume":"57","author":"R Duncan","year":"2005","unstructured":"Duncan, R. & Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57, 2215\u20132237, (2005).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR361","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12272-018-1008-4","volume":"41","author":"Y Kim","year":"2018","unstructured":"Kim, Y., Park, E. J. & Na, D. H. Recent progress in dendrimer-based nanomedicine development. Arch. Pharm. Res. 41, 571\u2013582 (2018).","journal-title":"Arch. Pharm. Res."},{"key":"2112_CR362","doi-asserted-by":"publisher","first-page":"10952","DOI":"10.1039\/C8NR01928B","volume":"10","author":"MA Deriu","year":"2018","unstructured":"Deriu, M. A. et al. Elucidating the role of surface chemistry on cationic phosphorus dendrimer-siRNA complexation. Nanoscale 10, 10952\u201310962 (2018).","journal-title":"Nanoscale"},{"key":"2112_CR363","doi-asserted-by":"publisher","DOI":"10.1186\/1556-276X-9-247","volume":"9","author":"E Abbasi","year":"2014","unstructured":"Abbasi, E. et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 9, 247 (2014).","journal-title":"Nanoscale Res Lett."},{"key":"2112_CR364","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41596-020-00418-9","volume":"16","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells. Nat. Protoc. 16, 327\u2013351 (2021).","journal-title":"Nat. Protoc."},{"key":"2112_CR365","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1021\/acsomega.9b00384","volume":"4","author":"NG Patil","year":"2019","unstructured":"Patil, N. G. et al. Synthesis of Stimuli-Responsive Heterofunctional Dendrimer by Passerini Multicomponent Reaction. ACS Omega 4, 6660\u20136668 (2019).","journal-title":"ACS Omega"},{"key":"2112_CR366","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cis.2018.06.005","volume":"257","author":"LJ Fox","year":"2018","unstructured":"Fox, L. J., Richardson, R. M. & Briscoe, W. H. PAMAM dendrimer - cell membrane interactions. Adv. Colloid Interf. Sci. 257, 1\u201318 (2018).","journal-title":"Adv. Colloid Interf. Sci."},{"key":"2112_CR367","first-page":"3361","volume":"6","author":"N Shao","year":"2011","unstructured":"Shao, N. et al. Comparison of generation 3 polyamidoamine dendrimer and generation 4 polypropylenimine dendrimer on drug loading, complex structure, release behavior, and cytotoxicity. Int J. Nanomed. 6, 3361\u20133372, (2011).","journal-title":"Int J. Nanomed."},{"key":"2112_CR368","doi-asserted-by":"publisher","first-page":"46290","DOI":"10.1021\/acsami.2c13129","volume":"14","author":"W Liyanage","year":"2022","unstructured":"Liyanage, W., Wu, T., Kannan, S. & Kannan, R. M. Dendrimer-siRNA Conjugates for Targeted Intracellular Delivery in Glioblastoma Animal Models. ACS Appl. Mater. Interf. 14, 46290\u201346303 (2022).","journal-title":"ACS Appl. Mater. Interf."},{"key":"2112_CR369","volume":"3","author":"MG Nussbaumer","year":"2016","unstructured":"Nussbaumer, M. G. et al. Chaperonin-Dendrimer Conjugates for siRNA Delivery. Adv. Sci. (Weinh.) 3, 1600046 (2016).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2112_CR370","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202003523","volume":"33","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Nanoassemblies with Effective Serum Tolerance Capability Achieving Robust Gene Silencing Efficacy for Breast Cancer Gene Therapy. Adv. Mater. 33, e2003523 (2021).","journal-title":"Adv. Mater."},{"key":"2112_CR371","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.biomaterials.2013.11.026","volume":"35","author":"ER Figueroa","year":"2014","unstructured":"Figueroa, E. R. et al. Optimization of PAMAM-gold nanoparticle conjugation for gene therapy. Biomaterials 35, 1725\u20131734 (2014).","journal-title":"Biomaterials"},{"key":"2112_CR372","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120000","volume":"246","author":"W Lee","year":"2020","unstructured":"Lee, W. et al. Dual peptide-dendrimer conjugate inhibits acetylation of transforming growth factor \u03b2-induced protein and improves survival in sepsis. Biomaterials 246, 120000 (2020).","journal-title":"Biomaterials"},{"key":"2112_CR373","doi-asserted-by":"publisher","first-page":"12168","DOI":"10.3390\/molecules181012168","volume":"18","author":"A Harada","year":"2013","unstructured":"Harada, A. et al. Intracellular environment-responsive stabilization of polymer vesicles formed from head-tail type polycations composed of a polyamidoamine dendron and poly(L-lysine). Molecules 18, 12168\u201312179 (2013).","journal-title":"Molecules"},{"key":"2112_CR374","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.carbpol.2017.12.049","volume":"184","author":"LJ L\u00f3pez-M\u00e9ndez","year":"2018","unstructured":"L\u00f3pez-M\u00e9ndez, L. J. et al. Synthesis of a poly(ester) dendritic \u03b2-cyclodextrin derivative by \u201cclick\u201d chemistry: Combining the best of two worlds for complexation enhancement. Carbohydr. Polym. 184, 20\u201329 (2018).","journal-title":"Carbohydr. Polym."},{"key":"2112_CR375","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1039\/b913281n","volume":"39","author":"G Franc","year":"2010","unstructured":"Franc, G. & Kakkar, A. K. Click\u201d methodologies: efficient, simple and greener routes to design dendrimers. Chem. Soc. Rev. 39, 1536\u20131544, (2010).","journal-title":"Chem. Soc. Rev."},{"key":"2112_CR376","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41557-023-01386-9","volume":"16","author":"PHS Paioti","year":"2024","unstructured":"Paioti, P. H. S. et al. Click processes orthogonal to CuAAC and SuFEx forge selectively modifiable fluorescent linkers. Nat. Chem. 16, 426\u2013436 (2024).","journal-title":"Nat. Chem."},{"key":"2112_CR377","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, 640\u2013655 (2020).","journal-title":"Science"},{"key":"2112_CR378","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0005-2736(81)90512-5","volume":"645","author":"EG Trams","year":"1981","unstructured":"Trams, E. G., Lauter, C. J., Salem, N. Jr & Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys. Acta 645, 63\u201370 (1981).","journal-title":"Biochim Biophys. Acta"},{"key":"2112_CR379","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI81135","volume":"126","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Invest 126, 1208\u20131215 (2016).","journal-title":"J. Clin. Invest"},{"key":"2112_CR380","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu, M., Martin-Jaular, L., Lavieu, G. & Th\u00e9ry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9\u201317 (2019).","journal-title":"Nat. Cell Biol."},{"key":"2112_CR381","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel, G., D\u2019Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213\u2013228 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR382","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jconrel.2014.12.013","volume":"199","author":"T Smyth","year":"2015","unstructured":"Smyth, T. et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control Release 199, 145\u2013155 (2015).","journal-title":"J. Control Release"},{"key":"2112_CR383","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","volume":"20","author":"M Cully","year":"2021","unstructured":"Cully, M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20, 6\u20137 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR384","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59\u201374 (1977).","journal-title":"J. Gen. Virol."},{"key":"2112_CR385","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"2112_CR386","doi-asserted-by":"publisher","first-page":"e99263","DOI":"10.1172\/jci.insight.99263","volume":"3","author":"M Mendt","year":"2018","unstructured":"Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263 (2018).","journal-title":"JCI Insight"},{"key":"2112_CR387","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1324730","volume":"6","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).","journal-title":"J. Extracell. Vesicles"},{"key":"2112_CR388","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2018024877","volume":"3","author":"EJ Park","year":"2019","unstructured":"Park, E. J. et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 3, 1\u201311 (2019).","journal-title":"Blood Adv."},{"key":"2112_CR389","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122558","volume":"308","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Exosome\/antimicrobial peptide laden hydrogel wound dressings promote scarless wound healing through miR-21-5p-mediated multiple functions. Biomaterials 308, 122558 (2024).","journal-title":"Biomaterials"},{"key":"2112_CR390","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1039\/D1BM01723C","volume":"10","author":"SF Liang","year":"2022","unstructured":"Liang, S. F., Zuo, F. F., Yin, B. C. & Ye, B. C. Delivery of siRNA based on engineered exosomes for glioblastoma therapy by targeting STAT3. Biomater. Sci. 10, 1582\u20131590 (2022).","journal-title":"Biomater. Sci."},{"key":"2112_CR391","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2019.11.009","volume":"317","author":"G Kim","year":"2020","unstructured":"Kim, G. et al. Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. J. Control Release 317, 273\u2013281 (2020).","journal-title":"J. Control Release"},{"key":"2112_CR392","doi-asserted-by":"publisher","first-page":"105218","DOI":"10.1016\/j.nbd.2020.105218","volume":"148","author":"J Yang","year":"2021","unstructured":"Yang, J. et al. Exosome-mediated delivery of antisense oligonucleotides targeting \u03b1-synuclein ameliorates the pathology in a mouse model of Parkinson\u2019s disease. Neurobiol. Dis. 148, 105218 (2021).","journal-title":"Neurobiol. Dis."},{"key":"2112_CR393","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.ymthe.2021.10.009","volume":"30","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. sEVs(RVG) selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model. Mol. Ther. 30, 2078\u20132091 (2022).","journal-title":"Mol. Ther."},{"key":"2112_CR394","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1016\/j.ymthe.2019.08.010","volume":"27","author":"M Izco","year":"2019","unstructured":"Izco, M. et al. Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. Mol. Ther. 27, 2111\u20132122 (2019).","journal-title":"Mol. Ther."},{"key":"2112_CR395","first-page":"138","volume":"34","author":"G Han","year":"2024","unstructured":"Han, G. et al. Oral TNF-\u03b1 siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease. Bioact. Mater. 34, 138\u2013149 (2024).","journal-title":"Bioact. Mater."},{"key":"2112_CR396","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01745-0","volume":"17","author":"N Lai","year":"2020","unstructured":"Lai, N. et al. Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice. J. Neuroinflamm. 17, 74 (2020).","journal-title":"J. Neuroinflamm."},{"key":"2112_CR397","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","volume":"318","author":"L Zhao","year":"2020","unstructured":"Zhao, L. et al. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J. Control Release 318, 1\u201315 (2020).","journal-title":"J. Control Release"},{"key":"2112_CR398","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1021\/acsnano.1c05505","volume":"16","author":"T Tian","year":"2022","unstructured":"Tian, T. et al. Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles. ACS Nano 16, 1940\u20131953 (2022).","journal-title":"ACS Nano"},{"key":"2112_CR399","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.apsb.2022.11.019","volume":"13","author":"N Uddin","year":"2023","unstructured":"Uddin, N. et al. Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome. Acta Pharm. Sin. B 13, 1383\u20131399 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2112_CR400","doi-asserted-by":"publisher","first-page":"e006166","DOI":"10.1136\/jitc-2022-006166","volume":"11","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition. J. Immunother Cancer 11, e006166 (2023).","journal-title":"J. Immunother Cancer"},{"key":"2112_CR401","volume":"9","author":"S Shan","year":"2022","unstructured":"Shan, S. et al. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. Adv. Sci. (Weinh.) 9, e2200353 (2022).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2112_CR402","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2019.02.011","volume":"449","author":"F Aqil","year":"2019","unstructured":"Aqil, F. et al. Milk exosomes - Natural nanoparticles for siRNA delivery. Cancer Lett. 449, 186\u2013195 (2019).","journal-title":"Cancer Lett."},{"key":"2112_CR403","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121306","volume":"280","author":"W Zhou","year":"2022","unstructured":"Zhou, W. et al. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Biomaterials 280, 121306 (2022).","journal-title":"Biomaterials"},{"key":"2112_CR404","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120369","volume":"264","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Exosome-mediated RNAi of PAK4 prolongs survival of pancreatic cancer mouse model after loco-regional treatment. Biomaterials 264, 120369 (2021).","journal-title":"Biomaterials"},{"key":"2112_CR405","first-page":"207","volume":"10","author":"Y Cui","year":"2022","unstructured":"Cui, Y. et al. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact. Mater. 10, 207\u2013221 (2022).","journal-title":"Bioact. Mater."},{"key":"2112_CR406","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/nprot.2012.131","volume":"7","author":"S El-Andaloussi","year":"2012","unstructured":"El-Andaloussi, S. et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7, 2112\u20132126 (2012).","journal-title":"Nat. Protoc."},{"key":"2112_CR407","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2019.08.021","volume":"311-312","author":"Z Zheng","year":"2019","unstructured":"Zheng, Z. et al. Folate-displaying exosome mediated cytosolic delivery of siRNA avoiding endosome trapping. J. Control Release 311-312, 43\u201349 (2019).","journal-title":"J. Control Release"},{"key":"2112_CR408","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.07.011","volume":"142","author":"D Yuan","year":"2017","unstructured":"Yuan, D. et al. Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain. Biomaterials 142, 1\u201312 (2017).","journal-title":"Biomaterials"},{"key":"2112_CR409","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1600-0854.2010.01041.x","volume":"11","author":"D Feng","year":"2010","unstructured":"Feng, D. et al. Cellular internalization of exosomes occurs through phagocytosis. Traffic 11, 675\u2013687 (2010).","journal-title":"Traffic"},{"key":"2112_CR410","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.biomaterials.2017.10.012","volume":"150","author":"T Tian","year":"2018","unstructured":"Tian, T. et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials 150, 137\u2013149 (2018).","journal-title":"Biomaterials"},{"key":"2112_CR411","doi-asserted-by":"publisher","first-page":"8926","DOI":"10.7150\/thno.62330","volume":"11","author":"M Xu","year":"2021","unstructured":"Xu, M. et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics 11, 8926\u20138944 (2021).","journal-title":"Theranostics"},{"key":"2112_CR412","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-019-0563-2","volume":"18","author":"G Liang","year":"2020","unstructured":"Liang, G. et al. Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J. Nanobiotechnol. 18, 10 (2020).","journal-title":"J. Nanobiotechnol."},{"key":"2112_CR413","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00331-0","volume":"26","author":"X Li","year":"2022","unstructured":"Li, X. et al. A drug delivery system constructed by a fusion peptide capturing exosomes targets to titanium implants accurately resulting the enhancement of osseointegration peri-implant. Biomater. Res. 26, 89 (2022).","journal-title":"Biomater. Res."},{"key":"2112_CR414","doi-asserted-by":"publisher","first-page":"121137","DOI":"10.1016\/j.biomaterials.2021.121137","volume":"278","author":"GR Gunassekaran","year":"2021","unstructured":"Gunassekaran, G. R., Poongkavithai Vadevoo, S. M., Baek, M. C. & Lee, B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278, 121137 (2021).","journal-title":"Biomaterials"},{"key":"2112_CR415","first-page":"766","volume":"25","author":"N Ran","year":"2023","unstructured":"Ran, N. et al. Autologous exosome facilitates load and target delivery of bioactive peptides to repair spinal cord injury. Bioact. Mater. 25, 766\u2013782 (2023).","journal-title":"Bioact. Mater."},{"key":"2112_CR416","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41551-020-00637-1","volume":"4","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Treatment of infarcted heart tissue via the capture and local delivery of circulating exosomes through antibody-conjugated magnetic nanoparticles. Nat. Biomed. Eng. 4, 1063\u20131075 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"2112_CR417","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","volume":"6","author":"D Ha","year":"2016","unstructured":"Ha, D., Yang, N. & Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm. Sin. B 6, 287\u2013296, (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"2112_CR418","doi-asserted-by":"publisher","first-page":"e12194","DOI":"10.1002\/jev2.12194","volume":"11","author":"S Ruan","year":"2022","unstructured":"Ruan, S., Erwin, N. & He, M. Light-induced high-efficient cellular production of immune functional extracellular vesicles. J. Extracell. Vesicles 11, e12194 (2022).","journal-title":"J. Extracell. Vesicles"},{"key":"2112_CR419","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03733-8","volume":"9","author":"R Kojima","year":"2018","unstructured":"Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson\u2019s disease treatment. Nat. Commun. 9, 1305 (2018).","journal-title":"Nat. Commun."},{"key":"2112_CR420","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","volume":"4","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat. Biomed. Eng. 4, 69\u201383 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"2112_CR421","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1021\/nn402232g","volume":"7","author":"SC Jang","year":"2013","unstructured":"Jang, S. C. et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 7, 7698\u20137710 (2013).","journal-title":"ACS Nano"},{"key":"2112_CR422","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1180","volume":"2","author":"L Balaj","year":"2011","unstructured":"Balaj, L. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).","journal-title":"Nat. Commun."},{"key":"2112_CR423","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04791-8","volume":"9","author":"WM Usman","year":"2018","unstructured":"Usman, W. M. et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat. Commun. 9, 2359 (2018).","journal-title":"Nat. Commun."},{"key":"2112_CR424","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","volume":"42","author":"YS Zhu","year":"2021","unstructured":"Zhu, Y. S., Tang, K. & Lv, J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharm. Sci. 42, 857\u2013869 (2021).","journal-title":"Trends Pharm. Sci."},{"key":"2112_CR425","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1002\/cam4.4052","volume":"10","author":"WQ Li","year":"2021","unstructured":"Li, W. Q. et al. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med. 10, 4677\u20134696 (2021).","journal-title":"Cancer Med."},{"key":"2112_CR426","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med. 382, 1507\u20131519 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR427","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs, S. F. et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N. Engl. J. Med. 384, 1216\u20131226 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR428","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani, M. et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N. Engl. J. Med. 382, 2289\u20132301 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR429","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1039\/D2CS00788F","volume":"52","author":"V Kumar","year":"2023","unstructured":"Kumar, V. & Turnbull, W. B. Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions. Chem. Soc. Rev. 52, 1273\u20131287 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"2112_CR430","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1126\/science.186.4161.365","volume":"186","author":"RJ Stockert","year":"1974","unstructured":"Stockert, R. J., Morell, A. G. & Scheinberg, I. H. Mammalian hepatic lectin. Science 186, 365\u2013366, (1974).","journal-title":"Science"},{"key":"2112_CR431","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1016\/S0021-9258(20)79761-9","volume":"249","author":"RL Hudgin","year":"1974","unstructured":"Hudgin, R. L. et al. The isolation and properties of a rabbit liver binding protein specific for asialoglycoproteins. J. Biol. Chem. 249, 5536\u20135543 (1974).","journal-title":"J. Biol. Chem."},{"key":"2112_CR432","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1016\/S0021-9258(19)85538-2","volume":"255","author":"JU Baenziger","year":"1980","unstructured":"Baenziger, J. U. & Maynard, Y. Human hepatic lectin. Physiochemical properties and specificity. J. Biol. Chem. 255, 4607\u20134613, (1980).","journal-title":"J. Biol. Chem."},{"key":"2112_CR433","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1006\/jmbi.2000.3853","volume":"300","author":"M Meier","year":"2000","unstructured":"Meier, M. et al. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J. Mol. Biol. 300, 857\u2013865 (2000).","journal-title":"J. Mol. Biol."},{"key":"2112_CR434","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1074\/jbc.M808689200","volume":"284","author":"LM Steirer","year":"2009","unstructured":"Steirer, L. M., Park, E. I., Townsend, R. R. & Baenziger, J. U. The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2,6-galactose. J. Biol. Chem. 284, 3777\u20133783 (2009).","journal-title":"J. Biol. Chem."},{"key":"2112_CR435","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/acscentsci.1c00146","volume":"7","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins. ACS Cent. Sci. 7, 499\u2013506 (2021).","journal-title":"ACS Cent. Sci."},{"key":"2112_CR436","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0021-9258(18)33240-X","volume":"258","author":"YC Lee","year":"1983","unstructured":"Lee, Y. C. et al. Binding of synthetic oligosaccharides to the hepatic Gal\/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258, 199\u2013202 (1983).","journal-title":"J. Biol. Chem."},{"key":"2112_CR437","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1021\/jm00009a014","volume":"38","author":"EA Biessen","year":"1995","unstructured":"Biessen, E. A. et al. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J. Med Chem. 38, 1538\u20131546 (1995).","journal-title":"J. Med Chem."},{"key":"2112_CR438","doi-asserted-by":"publisher","first-page":"37577","DOI":"10.1074\/jbc.M101786200","volume":"276","author":"PC Rensen","year":"2001","unstructured":"Rensen, P. C. et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276, 37577\u201337584 (2001).","journal-title":"J. Biol. Chem."},{"key":"2112_CR439","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","volume":"6","author":"Y Huang","year":"2017","unstructured":"Huang, Y. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics. Mol. Ther. Nucleic Acids 6, 116\u2013132 (2017).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR440","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker, A. J. et al. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Mol. Ther. 28, 1759\u20131771 (2020).","journal-title":"Mol. Ther."},{"key":"2112_CR441","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1016\/S0021-9258(18)34710-0","volume":"257","author":"AL Schwartz","year":"1982","unstructured":"Schwartz, A. L., Fridovich, S. E. & Lodish, H. F. Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J. Biol. Chem. 257, 4230\u20134237 (1982).","journal-title":"J. Biol. Chem."},{"key":"2112_CR442","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2018.0753","volume":"29","author":"ST Crooke","year":"2019","unstructured":"Crooke, S. T. et al. Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2\u2019-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Ther. 29, 16\u201332 (2019).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR443","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/jpet.115.230300","volume":"357","author":"A Watanabe","year":"2016","unstructured":"Watanabe, A. et al. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B. J. Pharm. Exp. Ther. 357, 320\u2013330 (2016).","journal-title":"J. Pharm. Exp. Ther."},{"key":"2112_CR444","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash, T. P. et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796\u20138807 (2014).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR445","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/nbt1339","volume":"25","author":"C Wolfrum","year":"2007","unstructured":"Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149\u20131157 (2007).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR446","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/mt.2008.14","volume":"16","author":"K Nishina","year":"2008","unstructured":"Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734\u2013740 (2008).","journal-title":"Mol. Ther."},{"key":"2112_CR447","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.omtn.2019.02.024","volume":"16","author":"J Scharner","year":"2019","unstructured":"Scharner, J. et al. Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor. Mol. Ther. Nucleic Acids 16, 313\u2013325 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR448","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jconrel.2019.03.028","volume":"302","author":"A Biscans","year":"2019","unstructured":"Biscans, A., Coles, A., Echeverria, D. & Khvorova, A. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. J. Control Release 302, 116\u2013125 (2019).","journal-title":"J. Control Release"},{"key":"2112_CR449","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1021\/nl9002969","volume":"9","author":"PO Anikeeva","year":"2009","unstructured":"Anikeeva, P. O., Halpert, J. E., Bawendi, M. G. & Bulovi\u0107, V. Quantum dot light-emitting devices with electroluminescence tunable over the entire visible spectrum. Nano Lett. 9, 2532\u20132536, (2009).","journal-title":"Nano Lett."},{"key":"2112_CR450","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/smll.201100474","volume":"7","author":"Y Gao","year":"2011","unstructured":"Gao, Y. & Tang, Z. Design and application of inorganic nanoparticle superstructures: current status and future challenges. Small 7, 2133\u20132146 (2011).","journal-title":"Small"},{"key":"2112_CR451","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1039\/D1NR06991H","volume":"14","author":"BE Ferdows","year":"2022","unstructured":"Ferdows, B. E. et al. RNA cancer nanomedicine: nanotechnology-mediated RNA therapy. Nanoscale 14, 4448\u20134455 (2022).","journal-title":"Nanoscale"},{"key":"2112_CR452","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114730","volume":"195","author":"CM Hirschbiegel","year":"2023","unstructured":"Hirschbiegel, C. M. et al. Inorganic nanoparticles as scaffolds for bioorthogonal catalysts. Adv. Drug Deliv. Rev. 195, 114730 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR453","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/anie.201002969","volume":"50","author":"AS Karakoti","year":"2011","unstructured":"Karakoti, A. S., Das, S., Thevuthasan, S. & Seal, S. PEGylated inorganic nanoparticles. Angew. Chem. Int Ed. Engl. 50, 1980\u20131994, (2011).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR454","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1021\/acs.nanolett.8b04677","volume":"19","author":"X He","year":"2019","unstructured":"He, X. et al. AIE Featured Inorganic-Organic Core@Shell Nanoparticles for High-Efficiency siRNA Delivery and Real-Time Monitoring. Nano Lett. 19, 2272\u20132279 (2019).","journal-title":"Nano Lett."},{"key":"2112_CR455","doi-asserted-by":"publisher","first-page":"13521","DOI":"10.1002\/anie.201708190","volume":"56","author":"Z Luo","year":"2017","unstructured":"Luo, Z. et al. Evolution of the Ligand Shell Morphology during Ligand Exchange Reactions on Gold Nanoparticles. Angew. Chem. Int. Ed. Engl. 56, 13521\u201313525 (2017).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2112_CR456","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1021\/acs.accounts.3c00255","volume":"56","author":"A Gupta","year":"2023","unstructured":"Gupta, A. et al. Interfacing Nanomaterials with Biology through Ligand Engineering. Acc. Chem. Res. 56, 2151\u20132169 (2023).","journal-title":"Acc. Chem. Res."},{"key":"2112_CR457","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1021\/cr0300789","volume":"105","author":"JC Love","year":"2005","unstructured":"Love, J. C. et al. Self-assembled monolayers of thiolates on metals as a form of nanotechnology. Chem. Rev. 105, 1103\u20131169, (2005).","journal-title":"Chem. Rev."},{"key":"2112_CR458","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/cr030698+","volume":"104","author":"MC Daniel","year":"2004","unstructured":"Daniel, M. C. & Astruc, D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem. Rev. 104, 293\u2013346 (2004).","journal-title":"Chem. Rev."},{"key":"2112_CR459","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/smll.200700217","volume":"4","author":"TS Hauck","year":"2008","unstructured":"Hauck, T. S., Ghazani, A. A. & Chan, W. C. Assessing the effect of surface chemistry on gold nanorod uptake, toxicity, and gene expression in mammalian cells. Small 4, 153\u2013159 (2008).","journal-title":"Small"},{"key":"2112_CR460","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/smll.200700378","volume":"3","author":"Y Pan","year":"2007","unstructured":"Pan, Y. et al. Size-dependent cytotoxicity of gold nanoparticles. Small 3, 1941\u20131949 (2007).","journal-title":"Small"},{"key":"2112_CR461","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202300098","volume":"7","author":"N Groysbeck","year":"2023","unstructured":"Groysbeck, N. et al. Bioactivated and PEG-Protected Circa 2 nm Gold Nanoparticles for in Cell Labelling and Cryo-Electron Microscopy. Small Methods 7, e2300098 (2023).","journal-title":"Small Methods"},{"key":"2112_CR462","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/mtomcs\/mfac031","volume":"14","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Size- and surface chemistry-dependent pharmacokinetics and tumor accumulation of engineered gold nanoparticles after intravenous administration. Metallomics 14, 516\u2013524 (2022).","journal-title":"Metallomics"},{"key":"2112_CR463","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.2147\/IJN.S175076","volume":"13","author":"V Vio","year":"2018","unstructured":"Vio, V. et al. Gold nanorods\/siRNA complex administration for knockdown of PARP-1: a potential treatment for perinatal asphyxia. Int J. Nanomed. 13, 6839\u20136854 (2018).","journal-title":"Int J. Nanomed."},{"key":"2112_CR464","doi-asserted-by":"publisher","first-page":"14096","DOI":"10.1021\/acsami.6b02548","volume":"8","author":"A Gupta","year":"2016","unstructured":"Gupta, A. et al. Ultrastable and Biofunctionalizable Gold Nanoparticles. ACS Appl Mater. Interf. 8, 14096\u201314101 (2016).","journal-title":"ACS Appl Mater. Interf."},{"key":"2112_CR465","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejpb.2018.08.012","volume":"131","author":"S Lee","year":"2018","unstructured":"Lee, S. et al. Controlled drug release with surface-capped mesoporous silica nanoparticles and its label-free in situ Raman monitoring. Eur. J. Pharm. Biopharm. 131, 232\u2013239 (2018).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2112_CR466","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jconrel.2006.06.017","volume":"114","author":"T Niidome","year":"2006","unstructured":"Niidome, T. et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Control Release 114, 343\u2013347 (2006).","journal-title":"J. Control Release"},{"key":"2112_CR467","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2009.06.006","volume":"139","author":"Y Akiyama","year":"2009","unstructured":"Akiyama, Y., Mori, T., Katayama, Y. & Niidome, T. The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice. J. Control Release 139, 81\u201384 (2009).","journal-title":"J. Control Release"},{"key":"2112_CR468","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1021\/mp3005885","volume":"10","author":"AJ Mieszawska","year":"2013","unstructured":"Mieszawska, A. J., Mulder, W. J., Fayad, Z. A. & Cormode, D. P. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 10, 831\u2013847, (2013).","journal-title":"Mol. Pharm."},{"key":"2112_CR469","doi-asserted-by":"publisher","first-page":"14066","DOI":"10.1021\/ja904326j","volume":"131","author":"SE Lee","year":"2009","unstructured":"Lee, S. E. et al. Biologically functional cationic phospholipid-gold nanoplasmonic carriers of RNA. J. Am. Chem. Soc. 131, 14066\u201314074 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR470","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/mt.2014.30","volume":"22","author":"Y Ding","year":"2014","unstructured":"Ding, Y. et al. Gold nanoparticles for nucleic acid delivery. Mol. Ther. 22, 1075\u20131083 (2014).","journal-title":"Mol. Ther."},{"key":"2112_CR471","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1021\/ja808719p","volume":"131","author":"DA Giljohann","year":"2009","unstructured":"Giljohann, D. A. et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J. Am. Chem. Soc. 131, 2072\u20132073 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR472","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/09205063.2023.2230841","volume":"34","author":"J Wan","year":"2023","unstructured":"Wan, J. et al. PEG-SH-GNPs-SAPNS@miR-29a delivery system promotes neural regeneration and recovery of motor function after spinal cord injury. J. Biomater. Sci. Polym. Ed. 34, 2107\u20132123 (2023).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"2112_CR473","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.973892","volume":"10","author":"W Chen","year":"2022","unstructured":"Chen, W. et al. Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion. Front Bioeng. Biotechnol. 10, 973892 (2022).","journal-title":"Front Bioeng. Biotechnol."},{"key":"2112_CR474","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-023-00434-2","volume":"27","author":"SJ Kim","year":"2023","unstructured":"Kim, S. J. et al. Axon guidance gene-targeted siRNA delivery system improves neural stem cell transplantation therapy after spinal cord injury. Biomater. Res. 27, 101 (2023).","journal-title":"Biomater. Res."},{"key":"2112_CR475","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","volume":"60","author":"II Slowing","year":"2008","unstructured":"Slowing, I. I., Vivero-Escoto, J. L., Wu, C. W. & Lin, V. S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60, 1278\u20131288 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR476","volume":"2022","author":"J Fu","year":"2022","unstructured":"Fu, J. et al. Silica Nanoparticles with Virus-Mimetic Spikes Enable Efficient siRNA Delivery In Vitro and In Vivo. Res. (Wash. D. C.) 2022, 0014 (2022).","journal-title":"Res. (Wash. D. C.)"},{"key":"2112_CR477","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1002\/adma.201400815","volume":"26","author":"D Niu","year":"2014","unstructured":"Niu, D. et al. Monodispersed and ordered large-pore mesoporous silica nanospheres with tunable pore structure for magnetic functionalization and gene delivery. Adv. Mater. 26, 4947\u20134953 (2014).","journal-title":"Adv. Mater."},{"key":"2112_CR478","doi-asserted-by":"publisher","DOI":"10.1016\/j.jenvman.2022.116221","volume":"324","author":"KBL Borchert","year":"2022","unstructured":"Borchert, K. B. L. et al. Tuning the pore structure of templated mesoporous poly(melamine-co-formaldehyde) particles toward diclofenac removal. J. Environ. Manag. 324, 116221 (2022).","journal-title":"J. Environ. Manag."},{"key":"2112_CR479","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/anie.201001037","volume":"50","author":"HF Krug","year":"2011","unstructured":"Krug, H. F. & Wick, P. Nanotoxicology: an interdisciplinary challenge. Angew. Chem. Int Ed. Engl. 50, 1260\u20131278, (2011).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR480","doi-asserted-by":"publisher","DOI":"10.1186\/s12989-021-00415-0","volume":"18","author":"M Inoue","year":"2021","unstructured":"Inoue, M. et al. Size and surface modification of silica nanoparticles affect the severity of lung toxicity by modulating endosomal ROS generation in macrophages. Part Fibre Toxicol. 18, 21 (2021).","journal-title":"Part Fibre Toxicol."},{"key":"2112_CR481","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jcis.2021.03.082","volume":"594","author":"A Khazieva","year":"2021","unstructured":"Khazieva, A. et al. Surface modification of silica nanoparticles by hexarhenium anionic cluster complexes for pH-sensing and staining of cell nuclei. J. Colloid Interf. Sci. 594, 759\u2013769 (2021).","journal-title":"J. Colloid Interf. Sci."},{"key":"2112_CR482","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1007\/s12274-018-2116-7","volume":"11","author":"R Kamegawa","year":"2018","unstructured":"Kamegawa, R., Naito, M. & Miyata, K. Functionalization of silica nanoparticles for nucleic acid delivery. Nano Res. 11, 5219\u20135239 (2018).","journal-title":"Nano Res."},{"key":"2112_CR483","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ijbiomac.2022.12.266","volume":"229","author":"P Kumar","year":"2023","unstructured":"Kumar, P., Salve, R., Paknikar, K. M. & Gajbhiye, V. Nucleolin aptamer conjugated MSNPs-PLR-PEG multifunctional nanoconstructs for targeted co-delivery of anticancer drug and siRNA to counter drug resistance in TNBC. Int J. Biol. Macromol. 229, 600\u2013614 (2023).","journal-title":"Int J. Biol. Macromol."},{"key":"2112_CR484","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.nano.2018.04.008","volume":"14","author":"SA Shahin","year":"2018","unstructured":"Shahin, S. A. et al. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14, 1381\u20131394 (2018).","journal-title":"Nanomedicine"},{"key":"2112_CR485","doi-asserted-by":"publisher","first-page":"16308","DOI":"10.1021\/acsnano.3c07621","volume":"17","author":"A Noureddine","year":"2023","unstructured":"Noureddine, A. et al. Future of Mesoporous Silica Nanoparticles in Nanomedicine: Protocol for Reproducible Synthesis, Characterization, Lipid Coating, and Loading of Therapeutics (Chemotherapeutic, Proteins, siRNA and mRNA). ACS Nano 17, 16308\u201316325 (2023).","journal-title":"ACS Nano"},{"key":"2112_CR486","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/10717544.2013.838715","volume":"21","author":"E Ahmadi","year":"2014","unstructured":"Ahmadi, E. et al. Synthesis and surface modification of mesoporous silica nanoparticles and its application as carriers for sustained drug delivery. Drug Deliv. 21, 164\u2013172 (2014).","journal-title":"Drug Deliv."},{"key":"2112_CR487","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni, J. A. et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16, 630\u2013643 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"2112_CR488","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102569","volume":"59","author":"A Abulikemu","year":"2023","unstructured":"Abulikemu, A. et al. Silica nanoparticles aggravated the metabolic associated fatty liver disease through disturbed amino acid and lipid metabolisms-mediated oxidative stress. Redox Biol. 59, 102569 (2023).","journal-title":"Redox Biol."},{"key":"2112_CR489","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2022.134633","volume":"300","author":"X Li","year":"2022","unstructured":"Li, X. et al. Long-term respiratory exposure to amorphous silica nanoparticles promoted systemic inflammation and progression of fibrosis in a susceptible mouse model. Chemosphere 300, 134633 (2022).","journal-title":"Chemosphere"},{"key":"2112_CR490","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115049","volume":"201","author":"A L\u00e9rida-Viso","year":"2023","unstructured":"L\u00e9rida-Viso, A. et al. Biosafety of mesoporous silica nanoparticles; towards clinical translation. Adv. Drug Deliv. Rev. 201, 115049 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR491","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1016\/j.biomaterials.2013.04.032","volume":"34","author":"J Duan","year":"2013","unstructured":"Duan, J. et al. Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model. Biomaterials 34, 5853\u20135862 (2013).","journal-title":"Biomaterials"},{"key":"2112_CR492","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.freeradbiomed.2022.02.027","volume":"182","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. Silica nanoparticles induce pyroptosis and cardiac hypertrophy via ROS\/NLRP3\/Caspase-1 pathway. Free Radic. Biol. Med. 182, 171\u2013181 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"2112_CR493","doi-asserted-by":"publisher","first-page":"124626","DOI":"10.1016\/j.jhazmat.2020.124626","volume":"406","author":"C Guo","year":"2021","unstructured":"Guo, C., Liu, Y. & Li, Y. Adverse effects of amorphous silica nanoparticles: Focus on human cardiovascular health. J. Hazard Mater. 406, 124626 (2021).","journal-title":"J. Hazard Mater."},{"key":"2112_CR494","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jconrel.2019.04.041","volume":"304","author":"R Mohammadpour","year":"2019","unstructured":"Mohammadpour, R. et al. Subchronic toxicity of silica nanoparticles as a function of size and porosity. J. Control Release 304, 216\u2013232 (2019).","journal-title":"J. Control Release"},{"key":"2112_CR495","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.actbio.2018.05.054","volume":"76","author":"C Pinese","year":"2018","unstructured":"Pinese, C. et al. Sustained delivery of siRNA\/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene silencing. Acta Biomater. 76, 164\u2013177 (2018).","journal-title":"Acta Biomater."},{"key":"2112_CR496","doi-asserted-by":"publisher","first-page":"13098","DOI":"10.1039\/C9NR03709H","volume":"11","author":"R Hufschmid","year":"2019","unstructured":"Hufschmid, R. et al. Observing the colloidal stability of iron oxide nanoparticles in situ. Nanoscale 11, 13098\u201313107 (2019).","journal-title":"Nanoscale"},{"key":"2112_CR497","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1021\/nn700344x","volume":"2","author":"N Insin","year":"2008","unstructured":"Insin, N. et al. Incorporation of iron oxide nanoparticles and quantum dots into silica microspheres. ACS Nano 2, 197\u2013202 (2008).","journal-title":"ACS Nano"},{"key":"2112_CR498","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/13543776.2022.2109413","volume":"32","author":"Z Mao","year":"2022","unstructured":"Mao, Z., Li, X., Wang, P. & Yan, H. Iron oxide nanoparticles for biomedical applications: an updated patent review (2015-2021). Expert Opin. Ther. Pat. 32, 939\u2013952 (2022).","journal-title":"Expert Opin. Ther. Pat."},{"key":"2112_CR499","doi-asserted-by":"publisher","first-page":"6620","DOI":"10.1039\/C6TB01462C","volume":"4","author":"J Li","year":"2016","unstructured":"Li, J., Xue, S. & Mao, Z. W. Nanoparticle delivery systems for siRNA-based therapeutics. J. Mater. Chem. B 4, 6620\u20136639 (2016).","journal-title":"J. Mater. Chem. B"},{"key":"2112_CR500","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3181\/00379727-158-40158","volume":"158","author":"KJ Widder","year":"1978","unstructured":"Widder, K. J., Senyel, A. E. & Scarpelli, G. D. Magnetic microspheres: a model system of site specific drug delivery in vivo. Proc. Soc. Exp. Biol. Med. 158, 141\u2013146 (1978).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"2112_CR501","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1063\/1.325219","volume":"49","author":"A Senyei","year":"1978","unstructured":"Senyei, A., Widder, K. & Czerlinski, G. Magnetic guidance of drug\u2010carrying microspheres. J. Appl. Phys. 49, 3578\u20133583 (1978).","journal-title":"J. Appl. Phys."},{"key":"2112_CR502","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/A:1006137523591","volume":"41","author":"SK Pulfer","year":"1999","unstructured":"Pulfer, S. K., Ciccotto, S. L. & Gallo, J. M. Distribution of small magnetic particles in brain tumor-bearing rats. J. Neurooncol. 41, 99\u2013105 (1999).","journal-title":"J. Neurooncol."},{"key":"2112_CR503","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1021\/acsami.2c17802","volume":"15","author":"S Chung","year":"2023","unstructured":"Chung, S., Sugimoto, Y., Huang, J. & Zhang, M. Iron Oxide Nanoparticles Decorated with Functional Peptides for a Targeted siRNA Delivery to Glioma Cells. ACS Appl Mater. Interf. 15, 106\u2013119 (2023).","journal-title":"ACS Appl Mater. Interf."},{"key":"2112_CR504","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202302851","volume":"13","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. A Biomimic Nanobullet with Ameliorative Inflammatory Microenvironment for Alzheimer\u2019s Disease Treatments. Adv. Health Mater. 13, e2302851 (2024).","journal-title":"Adv. Health Mater."},{"key":"2112_CR505","volume":"9","author":"B Li","year":"2022","unstructured":"Li, B. et al. Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome-Conjugated Magnetic Nanoparticles for Glioblastoma Therapy. Adv. Sci. (Weinh.) 9, e2105451 (2022).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2112_CR506","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.addr.2020.06.020","volume":"156","author":"DC Luther","year":"2020","unstructured":"Luther, D. C. et al. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv. Drug Deliv. Rev. 156, 188\u2013213 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR507","doi-asserted-by":"publisher","first-page":"100919","DOI":"10.1016\/j.pmatsci.2021.100919","volume":"125","author":"L-H Liu","year":"2022","unstructured":"Liu, L.-H. & Zhang, X.-Z. Carrier-free nanomedicines for cancer treatment. Prog. Mater Sci. 125, 100919 (2022).","journal-title":"Prog. Mater Sci."},{"key":"2112_CR508","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1128\/AAC.00014-09","volume":"53","author":"R Alvarez","year":"2009","unstructured":"Alvarez, R. et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother. 53, 3952\u20133962 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2112_CR509","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/mt.2013.216","volume":"22","author":"T Mart\u00ednez","year":"2014","unstructured":"Mart\u00ednez, T. et al. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol. Ther. 22, 81\u201391 (2014).","journal-title":"Mol. Ther."},{"key":"2112_CR510","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1002\/anie.201814289","volume":"58","author":"M Zheng","year":"2019","unstructured":"Zheng, M. et al. The siRNAsome: A Cation-Free and Versatile Nanostructure for siRNA and Drug Co-delivery. Angew. Chem. Int Ed. Engl. 58, 4938\u20134942 (2019).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"2112_CR511","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202301409","volume":"35","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Electrostatic Attractive Self-Delivery of siRNA and Light-Induced Self-Escape for Synergistic Gene Therapy. Adv. Mater. 35, e2301409 (2023).","journal-title":"Adv. Mater."},{"key":"2112_CR512","doi-asserted-by":"publisher","first-page":"23827","DOI":"10.1021\/acsnano.4c09027","volume":"18","author":"F Fang","year":"2024","unstructured":"Fang, F. & Chen, X. Carrier-Free Nanodrugs: From Bench to Bedside. ACS Nano. 18, 23827\u201323841 (2024).","journal-title":"ACS Nano."},{"key":"2112_CR513","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1089\/hum.2023.123","volume":"34","author":"A Galy","year":"2023","unstructured":"Galy, A. et al. Recent Advances Using Genetic Therapies Against Infectious Diseases and for Vaccination. Hum. Gene Ther. 34, 896\u2013904 (2023).","journal-title":"Hum. Gene Ther."},{"key":"2112_CR514","doi-asserted-by":"publisher","first-page":"20220012","DOI":"10.1002\/EXP.20220012","volume":"2","author":"H Forgham","year":"2022","unstructured":"Forgham, H., Kakinen, A., Qiao, R. & Davis, T. P. Keeping up with the COVID\u2019s\u2014Could siRNA-based antivirals be a part of the answer? Exploration 2, 20220012 (2022).","journal-title":"Exploration"},{"key":"2112_CR515","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.cell.2015.02.025","volume":"160","author":"JM Luna","year":"2015","unstructured":"Luna, J. M. et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 160, 1099\u20131110 (2015).","journal-title":"Cell"},{"key":"2112_CR516","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","volume":"62","author":"S Bandiera","year":"2015","unstructured":"Bandiera, S., Pfeffer, S., Baumert, T. F. & Zeisel, M. B. miR-122-a key factor and therapeutic target in liver disease. J. Hepatol. 62, 448\u2013457, (2015).","journal-title":"J. Hepatol."},{"key":"2112_CR517","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.chom.2014.07.006","volume":"16","author":"CD Sedano","year":"2014","unstructured":"Sedano, C. D. & Sarnow, P. Hepatitis C virus subverts liver-specific miR-122 to protect the viral genome from exoribonuclease Xrn2. Cell Host Microbe 16, 257\u2013264 (2014).","journal-title":"Cell Host Microbe"},{"key":"2112_CR518","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31008","volume":"72","author":"MF Yuen","year":"2020","unstructured":"Yuen, M. F. et al. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. Hepatology 72, 19\u201331 (2020).","journal-title":"Hepatology"},{"key":"2112_CR519","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","volume":"71","author":"MF Yuen","year":"2022","unstructured":"Yuen, M. F. et al. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut 71, 789\u2013797 (2022).","journal-title":"Gut"},{"key":"2112_CR520","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpdd.318","volume":"6","author":"T Schluep","year":"2017","unstructured":"Schluep, T. et al. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. Clin. Pharm. Drug Dev. 6, 350\u2013362 (2017).","journal-title":"Clin. Pharm. Drug Dev."},{"key":"2112_CR521","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001997","volume":"13","author":"J Dunning","year":"2016","unstructured":"Dunning, J. et al. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 13, e1001997 (2016).","journal-title":"PLoS Med."},{"key":"2112_CR522","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100300","volume":"3","author":"S Maestro","year":"2021","unstructured":"Maestro, S. et al. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 3, 100300 (2021).","journal-title":"JHEP Rep."},{"key":"2112_CR523","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","volume":"203","author":"AA D\u2019Souza","year":"2015","unstructured":"D\u2019Souza, A. A. & Devarajan, P. V. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. J. Control Release 203, 126\u2013139 (2015).","journal-title":"J. Control Release"},{"key":"2112_CR524","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jhep.2021.12.015","volume":"76","author":"A Gardin","year":"2022","unstructured":"Gardin, A. et al. Modern therapeutic approaches to liver-related disorders. J. Hepatol. 76, 1392\u20131409 (2022).","journal-title":"J. Hepatol."},{"key":"2112_CR525","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nbt0410-295","volume":"28","author":"J Kling","year":"2010","unstructured":"Kling, J. Safety signal dampens reception for mipomersen antisense. Nat. Biotechnol. 28, 295\u2013297, (2010).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR526","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","volume":"36","author":"RD Santos","year":"2015","unstructured":"Santos, R. D. et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 36, 566\u2013575 (2015).","journal-title":"Eur. Heart J."},{"key":"2112_CR527","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam, S. J. Inotersen: First Global Approval. Drugs 78, 1371\u20131376 (2018).","journal-title":"Drugs"},{"key":"2112_CR528","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/13506129.2021.1975673","volume":"28","author":"JH Marques","year":"2021","unstructured":"Marques, J. H., Coelho, J., Men\u00e9res, M. J. & Beir\u00e3o, J. M. Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis. Amyloid 28, 275\u2013276 (2021).","journal-title":"Amyloid"},{"key":"2112_CR529","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D. et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N. Engl. J. Med. 379, 22\u201331 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR530","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","volume":"269","author":"TH Brannagan","year":"2022","unstructured":"Brannagan, T. H. et al. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update. J. Neurol. 269, 6416\u20136427 (2022).","journal-title":"J. Neurol."},{"key":"2112_CR531","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMc1912350","volume":"381","author":"SA Khetarpal","year":"2019","unstructured":"Khetarpal, S. A., Wang, M. & Khera, A. V. Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. N. Engl. J. Med. 381, 2582\u20132584 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR532","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold, I. et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diab. Endocrinol. 9, 264\u2013275 (2021).","journal-title":"Lancet Diab. Endocrinol."},{"key":"2112_CR533","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum, J. L. et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N. Engl. J. Med 381, 531\u2013542 (2019).","journal-title":"N. Engl. J. Med"},{"key":"2112_CR534","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41569-023-00955-2","volume":"21","author":"I Fern\u00e1ndez-Ruiz","year":"2023","unstructured":"Fern\u00e1ndez-Ruiz, I. Patisiran is beneficial for the treatment of TTR cardiac amyloidosis. Nat. Rev. Cardiol 21, 8\u20138 (2023).","journal-title":"Nat. Rev. Cardiol"},{"key":"2112_CR535","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam, S. J. Vutrisiran: First Approval. Drugs 82, 1419\u20131425 (2022).","journal-title":"Drugs"},{"key":"2112_CR536","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMe2010986","volume":"382","author":"G Gonzalez-Aseguinolaza","year":"2020","unstructured":"Gonzalez-Aseguinolaza, G. Givosiran - Running RNA Interference to Fight Porphyria Attacks. N. Engl. J. Med. 382, 2366\u20132367 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR537","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed, Y. Y. Givosiran: A Review in Acute Hepatic Porphyria. Drugs 81, 841\u2013848 (2021).","journal-title":"Drugs"},{"key":"2112_CR538","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott, L. J. & Keam, S. J. Lumasiran: First Approval. Drugs 81, 277\u2013282 (2021).","journal-title":"Drugs"},{"key":"2112_CR539","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/eurheartj\/ehac656","volume":"44","author":"RD Santos","year":"2023","unstructured":"Santos, R. D. & Rocha, V. Z. Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book. Eur. Heart J. 44, 139\u2013141 (2023).","journal-title":"Eur. Heart J."},{"key":"2112_CR540","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41569-020-0373-0","volume":"17","author":"I Fern\u00e1ndez-Ruiz","year":"2020","unstructured":"Fern\u00e1ndez-Ruiz, I. Twice-yearly inclisiran injections halve LDL-cholesterol levels. Nat. Rev. Cardiol. 17, 321 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2112_CR541","doi-asserted-by":"publisher","first-page":"10203","DOI":"10.1073\/pnas.91.21.10203","volume":"91","author":"MA Castro-Alamancos","year":"1994","unstructured":"Castro-Alamancos, M. A. & Torres-Aleman, I. Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide. Proc. Natl Acad. Sci. USA 91, 10203\u201310207 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR542","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/02713689609017619","volume":"15","author":"PE Rakoczy","year":"1996","unstructured":"Rakoczy, P. E. et al. Initiation of impaired outer segment degradation in vivo using an antisense oligonucleotide. Curr. Eye Res. 15, 119\u2013123 (1996).","journal-title":"Curr. Eye Res."},{"key":"2112_CR543","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","volume":"57","author":"CM Perry","year":"1999","unstructured":"Perry, C. M. & Balfour, J. A. Fomivirsen. Drugs 57, 375\u2013380 (1999). discussion 381.","journal-title":"Drugs"},{"key":"2112_CR544","unstructured":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 133, 467\u2013474, (2002)."},{"key":"2112_CR545","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.21","volume":"1","author":"X Gerard","year":"2012","unstructured":"Gerard, X. et al. AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the Common Leber Congenital Amaurosis CEP290 Mutation. Mol. Ther. Nucleic Acids 1, e29 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR546","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.3","volume":"1","author":"RW Collin","year":"2012","unstructured":"Collin, R. W. et al. Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol. Ther. Nucleic Acids 1, e14 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR547","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","volume":"29","author":"K Xue","year":"2020","unstructured":"Xue, K. & MacLaren, R. E. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin. Investig. Drugs 29, 1163\u20131170 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2112_CR548","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.omtn.2023.05.020","volume":"32","author":"RTW Schellens","year":"2023","unstructured":"Schellens, R. T. W. et al. A protein domain-oriented approach to expand the opportunities of therapeutic exon skipping for USH2A-associated retinitis pigmentosa. Mol. Ther. Nucleic Acids 32, 980\u2013994 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR549","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1861-3","volume":"18","author":"K Lorenz","year":"2017","unstructured":"Lorenz, K. et al. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II\/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. Trials 18, 128 (2017).","journal-title":"Trials"},{"key":"2112_CR550","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.gt.3302641","volume":"13","author":"J Shen","year":"2006","unstructured":"Shen, J. et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther. 13, 225\u2013234 (2006).","journal-title":"Gene Ther."},{"key":"2112_CR551","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1039\/D3TB00930K","volume":"11","author":"SB He","year":"2023","unstructured":"He, S. B. et al. Advances and perspectives of nanozymes in respiratory diseases. J. Mater. Chem. B 11, 7041\u20137054 (2023).","journal-title":"J. Mater. Chem. B"},{"key":"2112_CR552","doi-asserted-by":"publisher","first-page":"113953","DOI":"10.1016\/j.addr.2021.113953","volume":"177","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Fern\u00e1ndez, A., Sancen\u00f3n, F. & Mart\u00ednez-M\u00e1\u00f1ez, R. Mesoporous silica nanoparticles for pulmonary drug delivery. Adv. Drug Deliv. Rev. 177, 113953 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR553","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijpharm.2018.05.070","volume":"547","author":"TS Patil","year":"2018","unstructured":"Patil, T. S. & Deshpande, A. S. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State-of-the-Art Review. Int J. Pharm. 547, 209\u2013225 (2018).","journal-title":"Int J. Pharm."},{"key":"2112_CR554","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jcf.2018.10.015","volume":"18","author":"I Sermet-Gaudelus","year":"2019","unstructured":"Sermet-Gaudelus, I. et al. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. J. Cyst. Fibros. 18, 536\u2013542 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"2112_CR555","doi-asserted-by":"publisher","first-page":"e0219182","DOI":"10.1371\/journal.pone.0219182","volume":"14","author":"W Beumer","year":"2019","unstructured":"Beumer, W. et al. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. PLoS One 14, e0219182 (2019).","journal-title":"PLoS One"},{"key":"2112_CR556","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jcf.2019.05.014","volume":"19","author":"P Drevinek","year":"2020","unstructured":"Drevinek, P. et al. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. J. Cyst. Fibros. 19, 99\u2013107 (2020).","journal-title":"J. Cyst. Fibros."},{"key":"2112_CR557","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3390\/antibiotics10050486","volume":"10","author":"RM Gir\u00f3n Moreno","year":"2021","unstructured":"Gir\u00f3n Moreno, R. M. et al. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 10, 486 (2021).","journal-title":"Antibiotics (Basel)"},{"key":"2112_CR558","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"2112_CR559","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi, M. S. et al. A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312\u2013319 (2009).","journal-title":"Exp. Neurol."},{"key":"2112_CR560","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.omtm.2020.09.003","volume":"19","author":"N Svrzikapa","year":"2020","unstructured":"Svrzikapa, N. et al. Investigational Assay for Haplotype Phasing of the Huntingtin Gene. Mol. Ther. Methods Clin. Dev. 19, 162\u2013173 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2112_CR561","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell, A. et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 128, 3558\u20133567 (2018).","journal-title":"J. Clin. Invest."},{"key":"2112_CR562","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller, T. M. et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 387, 1099\u20131110 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR563","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller, T. et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 383, 109\u2013119 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR564","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","volume":"24","author":"E Abati","year":"2020","unstructured":"Abati, E., Bresolin, N., Comi, G. & Corti, S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opin. Ther. Targets 24, 295\u2013310 (2020).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2112_CR565","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awac252","volume":"146","author":"A Pechmann","year":"2023","unstructured":"Pechmann, A. et al. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain 146, 668\u2013677 (2023).","journal-title":"Brain"},{"key":"2112_CR566","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel, R. S. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 377, 1723\u20131732 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR567","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel, R. S. et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388, 3017\u20133026 (2016).","journal-title":"Lancet"},{"key":"2112_CR568","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/mus.26633","volume":"60","author":"J Montes","year":"2019","unstructured":"Montes, J. et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 60, 409\u2013414 (2019).","journal-title":"Muscle Nerve"},{"key":"2112_CR569","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo, A. et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 19, 655\u2013667 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"2112_CR570","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/nar\/gkz140","volume":"47","author":"MM Janas","year":"2019","unstructured":"Janas, M. M. et al. Safety evaluation of 2\u2019-deoxy-2\u2019-fluoro nucleotides in GalNAc-siRNA conjugates. Nucleic Acids Res. 47, 3306\u20133320 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR571","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D. et al. Duchenne muscular dystrophy. Nat. Rev. Dis. Prim. 7, 13 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2112_CR572","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya, Y. et al. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Mol. Ther. 25, 2561\u20132572 (2017).","journal-title":"Mol. Ther."},{"key":"2112_CR573","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens, P. R. et al. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 77, 982\u2013991 (2020).","journal-title":"JAMA Neurol."},{"key":"2112_CR574","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1073\/pnas.86.9.3379","volume":"86","author":"G Anfossi","year":"1989","unstructured":"Anfossi, G., Gewirtz, A. M. & Calabretta, B. An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl Acad. Sci. USA 86, 3379\u20133383, (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR575","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1093\/nar\/26.23.5425","volume":"26","author":"L Tondelli","year":"1998","unstructured":"Tondelli, L. et al. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res. 26, 5425\u20135431 (1998).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR576","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1182\/blood.V99.4.1150","volume":"99","author":"SM Luger","year":"2002","unstructured":"Luger, S. M. et al. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood 99, 1150\u20131158 (2002).","journal-title":"Blood"},{"key":"2112_CR577","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","volume":"6","author":"MJ Reilley","year":"2018","unstructured":"Reilley, M. J. et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J. Immunother. Cancer 6, 119 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2112_CR578","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1016\/S0959-8049(16)33031-3","volume":"69","author":"S Chowdhury","year":"2016","unstructured":"Chowdhury, S. et al. A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR). Eur. J. Cancer. 69, S145 (2016).","journal-title":"Eur. J. Cancer."},{"key":"2112_CR579","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1158\/1535-7163.MCT-11-0329","volume":"10","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol. Cancer Ther. 10, 2309\u20132319 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"2112_CR580","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1021\/mp900015y","volume":"6","author":"ME Davis","year":"2009","unstructured":"Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659\u2013668 (2009).","journal-title":"Mol. Pharm."},{"key":"2112_CR581","doi-asserted-by":"publisher","first-page":"11449","DOI":"10.1073\/pnas.1411393111","volume":"111","author":"JE Zuckerman","year":"2014","unstructured":"Zuckerman, J. E. et al. Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl Acad. Sci. USA 111, 11449\u201311454 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR582","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd4685","volume":"14","author":"JE Zuckerman","year":"2015","unstructured":"Zuckerman, J. E. & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843\u2013856, (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR583","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1073\/pnas.1314307110","volume":"110","author":"E Zorde Khvalevsky","year":"2013","unstructured":"Zorde Khvalevsky, E. et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20723\u201320728 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR584","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.18632\/oncotarget.4183","volume":"6","author":"T Golan","year":"2015","unstructured":"Golan, T. et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 6, 24560\u201324570 (2015).","journal-title":"Oncotarget"},{"key":"2112_CR585","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","volume":"68","author":"M Aleku","year":"2008","unstructured":"Aleku, M. et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68, 9788\u20139798 (2008).","journal-title":"Cancer Res."},{"key":"2112_CR586","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","volume":"13","author":"A Santel","year":"2006","unstructured":"Santel, A. et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13, 1222\u20131234 (2006).","journal-title":"Gene Ther."},{"key":"2112_CR587","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","volume":"16","author":"A Santel","year":"2010","unstructured":"Santel, A. et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer Res 16, 5469\u20135480 (2010).","journal-title":"Clin. Cancer Res"},{"key":"2112_CR588","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","volume":"32","author":"B Schultheis","year":"2014","unstructured":"Schultheis, B. et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 32, 4141\u20134148 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2112_CR589","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-020-00944-9","volume":"13","author":"T Xiao","year":"2020","unstructured":"Xiao, T. et al. Targeting EphA2 in cancer. J. Hematol. Oncol. 13, 114 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"2112_CR590","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","volume":"65","author":"CN Landen Jr.","year":"2005","unstructured":"Landen, C. N. Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910\u20136918 (2005).","journal-title":"Cancer Res."},{"key":"2112_CR591","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1158\/1535-7163.MCT-16-0541","volume":"16","author":"MJ Wagner","year":"2017","unstructured":"Wagner, M. J. et al. Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol. Cancer Ther. 16, 1114\u20131123 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2112_CR592","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri, A., Wolf, E. & Eilers, M. Target gene-independent functions of MYC oncoproteins. Nat. Rev. Mol. Cell Biol. 21, 255\u2013267 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR593","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/mt.2008.98","volume":"16","author":"L Dor\u00e9-Savard","year":"2008","unstructured":"Dor\u00e9-Savard, L. et al. Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol. Ther. 16, 1331\u20131339 (2008).","journal-title":"Mol. Ther."},{"key":"2112_CR594","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovi\u0107","year":"2018","unstructured":"Jovanovi\u0107, K. K. et al. Targeting MYC in multiple myeloma. Leukemia 32, 1295\u20131306 (2018).","journal-title":"Leukemia"},{"key":"2112_CR595","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1053\/j.ajkd.2019.09.011","volume":"75","author":"AJ Miller","year":"2020","unstructured":"Miller, A. J., Chang, A. & Cunningham, P. N. Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA. Am. J. Kidney Dis. 75, 513\u2013516 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"2112_CR596","doi-asserted-by":"publisher","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","volume":"33","author":"AW Tolcher","year":"2015","unstructured":"Tolcher, A. W. et al. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. J. Clin. Oncol. 33, 11006\u201311006 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2112_CR597","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13046-021-02193-1","volume":"40","author":"R Cuciniello","year":"2021","unstructured":"Cuciniello, R., Filosa, S. & Crispi, S. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics. J. Exp. Clin. Cancer Res. 40, 383 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2112_CR598","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2174\/187152008785133119","volume":"8","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. & Xu, W. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem. 8, 698\u2013704 (2008).","journal-title":"Anticancer Agents Med Chem."},{"key":"2112_CR599","doi-asserted-by":"publisher","DOI":"10.1186\/0717-6287-47-70","volume":"47","author":"CC Doan","year":"2014","unstructured":"Doan, C. C. et al. Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells. Biol. Res 47, 70 (2014).","journal-title":"Biol. Res"},{"key":"2112_CR600","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1158\/1538-7445.AM10-4064","volume":"70","author":"I Toudjarska","year":"2010","unstructured":"Toudjarska, I. et al. Abstract 4064: Development of ALN-VSP: An RNAi therapeutic for solid tumors. Cancer Res. 70, 4064\u20134064 (2010).","journal-title":"Cancer Res."},{"key":"2112_CR601","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406\u2013417 (2013).","journal-title":"Cancer Discov."},{"key":"2112_CR602","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3748\/wjg.v18.i27.3527","volume":"18","author":"WC Mok","year":"2012","unstructured":"Mok, W. C., Wasser, S., Tan, T. & Lim, S. G. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J. Gastroenterol. 18, 3527\u20133536 (2012).","journal-title":"World J. Gastroenterol."},{"key":"2112_CR603","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1158\/1538-7445.AM2011-2829","volume":"71","author":"SC Semple","year":"2011","unstructured":"Semple, S. C. et al. Abstract 2829: Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1. Cancer Res. 71, 2829\u20132829 (2011).","journal-title":"Cancer Res."},{"key":"2112_CR604","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","volume":"182","author":"G Kara","year":"2022","unstructured":"Kara, G., Calin, G. A. & Ozpolat, B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv. Drug Deliv. Rev. 182, 114113 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR605","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR606","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat. Protoc. 18, 265\u2013291 (2023).","journal-title":"Nat. Protoc."},{"key":"2112_CR607","volume":"6","author":"D Ding","year":"2023","unstructured":"Ding, D. et al. The First-in-Human Whole-Body Dynamic Pharmacokinetics Study of Aptamer. Res.(Wash. D. C.) 6, 0126 (2023).","journal-title":"Res.(Wash. D. C.)"},{"key":"2112_CR608","doi-asserted-by":"crossref","unstructured":"Siddiqui, M. A. & Keating, G. M. Pegaptanib: in exudative age-related macular 39 degeneration. Drugs. 65, 1571\u20131577; discussion 1578\u20131579, (2005).","DOI":"10.2165\/00003495-200565110-00010"},{"key":"2112_CR609","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/nat.2015.0573","volume":"26","author":"DW Drolet","year":"2016","unstructured":"Drolet, D. W., Green, L. S., Gold, L. & Janjic, N. Fit for the Eye: Aptamers in Ocular Disorders. Nucleic Acid Ther. 26, 127\u2013146, (2016).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR610","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1023\/A:1007657109012","volume":"17","author":"DW Drolet","year":"2000","unstructured":"Drolet, D. W. et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm. Res 17, 1503\u20131510 (2000).","journal-title":"Pharm. Res"},{"key":"2112_CR611","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s004170050092","volume":"236","author":"U Schmidt-Erfurth","year":"1998","unstructured":"Schmidt-Erfurth, U. et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch. Clin. Exp. Ophthalmol. 236, 365\u2013374 (1998).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"2112_CR612","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s40265-023-01948-8","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang, C. Avacincaptad Pegol: First Approval. Drugs 83, 1447\u20131453 (2023).","journal-title":"Drugs"},{"key":"2112_CR613","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.chembiol.2024.03.011","volume":"31","author":"X Fu","year":"2024","unstructured":"Fu, X. et al. Repurposing AS1411 for constructing ANM-PROTACs. Cell Chem. Biol. 31, 1290\u20131304.e1297 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2112_CR614","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122620","volume":"309","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. Energy-storing DNA-based hydrogel remodels tumor microenvironments for laser-free photodynamic immunotherapy. Biomaterials 309, 122620 (2024).","journal-title":"Biomaterials"},{"key":"2112_CR615","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167211","volume":"1870","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. AS1411 binds to nucleolin via its parallel structure and disrupts the exos-miRNA-27a-mediated reciprocal activation loop between glioma and astrocytes. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 167211 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2112_CR616","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","volume":"123","author":"J Hoellenriegel","year":"2014","unstructured":"Hoellenriegel, J. et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123, 1032\u20131039 (2014).","journal-title":"Blood"},{"key":"2112_CR617","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2017.5","volume":"31","author":"H Ludwig","year":"2017","unstructured":"Ludwig, H. et al. Olaptesed pegol, an anti-CXCL12\/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed\/refractory multiple myeloma: a Phase IIa Study. Leukemia 31, 997\u20131000 (2017).","journal-title":"Leukemia"},{"key":"2112_CR618","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48416-9","volume":"15","author":"FA Giordano","year":"2024","unstructured":"Giordano, F. A. et al. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial. Nat. Commun. 15, 4210 (2024).","journal-title":"Nat. Commun."},{"key":"2112_CR619","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ymthe.2019.03.016","volume":"27","author":"SM Nimjee","year":"2019","unstructured":"Nimjee, S. M. et al. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Mol. Ther. 27, 1228\u20131241 (2019).","journal-title":"Mol. Ther."},{"key":"2112_CR620","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","volume":"114","author":"CK Dyke","year":"2006","unstructured":"Dyke, C. K. et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114, 2490\u20132497 (2006).","journal-title":"Circulation"},{"key":"2112_CR621","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","volume":"34","author":"TJ Povsic","year":"2013","unstructured":"Povsic, T. J. et al. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur. Heart J. 34, 2481\u20132489 (2013).","journal-title":"Eur. Heart J."},{"key":"2112_CR622","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","volume":"116","author":"JC Gilbert","year":"2007","unstructured":"Gilbert, J. C. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678\u20132686 (2007).","journal-title":"Circulation"},{"key":"2112_CR623","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","volume":"141","author":"TX Lu","year":"2018","unstructured":"Lu, T. X. & Rothenberg, M. E. MicroRNA. J. Allergy Clin. Immunol. 141, 1202\u20131207 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2112_CR624","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev.pathol.4.110807.092222","volume":"4","author":"YS Lee","year":"2009","unstructured":"Lee, Y. S. & Dutta, A. MicroRNAs in cancer. Annu Rev. Pathol. 4, 199\u2013227 (2009).","journal-title":"Annu Rev. Pathol."},{"key":"2112_CR625","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1146\/annurev-biochem-060308-103103","volume":"79","author":"MR Fabian","year":"2010","unstructured":"Fabian, M. R., Sonenberg, N. & Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu Rev. Biochem. 79, 351\u2013379, (2010).","journal-title":"Annu Rev. Biochem."},{"key":"2112_CR626","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.gpb.2012.07.005","volume":"10","author":"Y Li","year":"2012","unstructured":"Li, Y. & Kowdley, K. V. MicroRNAs in common human diseases. Genom. Proteom. Bioinf. 10, 246\u2013253 (2012).","journal-title":"Genom. Proteom. Bioinf."},{"key":"2112_CR627","doi-asserted-by":"publisher","first-page":"930","DOI":"10.7150\/thno.7026","volume":"3","author":"S Srinivasan","year":"2013","unstructured":"Srinivasan, S. et al. MicroRNAs -the next generation therapeutic targets in human diseases. Theranostics 3, 930\u2013942 (2013).","journal-title":"Theranostics"},{"key":"2112_CR628","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","volume":"368","author":"HL Janssen","year":"2013","unstructured":"Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685\u20131694 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2112_CR629","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.antiviral.2014.08.015","volume":"111","author":"MH van der Ree","year":"2014","unstructured":"van der Ree, M. H. et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antivir. Res. 111, 53\u201359 (2014).","journal-title":"Antivir. Res."},{"key":"2112_CR630","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1128\/AAC.04220-14","volume":"59","author":"S Ottosen","year":"2015","unstructured":"Ottosen, S. et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob. Agents Chemother. 59, 599\u2013608 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2112_CR631","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(16)31715-9","volume":"389","author":"MH van der Ree","year":"2017","unstructured":"van der Ree, M. H. et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet 389, 709\u2013717 (2017).","journal-title":"Lancet"},{"key":"2112_CR632","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/hep.29148","volume":"66","author":"F Stelma","year":"2017","unstructured":"Stelma, F. et al. Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101. Hepatology 66, 57\u201368 (2017).","journal-title":"Hepatology"},{"key":"2112_CR633","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Liao, Y. & Tang, L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J. Exp. Clin. Cancer Res. 38, 53 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2112_CR634","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","volume":"13","author":"CL Daige","year":"2014","unstructured":"Daige, C. L. et al. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol. Cancer Ther. 13, 2352\u20132360 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"2112_CR635","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fgene.2012.00120","volume":"3","author":"AG Bader","year":"2012","unstructured":"Bader, A. G. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 3, 120 (2012).","journal-title":"Front Genet."},{"key":"2112_CR636","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nrd4140","volume":"12","author":"H Ling","year":"2013","unstructured":"Ling, H., Fabbri, M. & Calin, G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847\u2013865, (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR637","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","volume":"122","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br. J. Cancer 122, 1630\u20131637 (2020).","journal-title":"Br. J. Cancer"},{"key":"2112_CR638","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104304","volume":"85","author":"M Chioccioli","year":"2022","unstructured":"Chioccioli, M. et al. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine 85, 104304 (2022).","journal-title":"EBioMedicine"},{"key":"2112_CR639","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/wrr.12660","volume":"26","author":"CL Gallant-Behm","year":"2018","unstructured":"Gallant-Behm, C. L. et al. A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds. Wound Repair Regen. 26, 311\u2013323 (2018).","journal-title":"Wound Repair Regen."},{"key":"2112_CR640","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2020.0871","volume":"30","author":"WT Abplanalp","year":"2020","unstructured":"Abplanalp, W. T. et al. Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 30, 335\u2013345 (2020).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR641","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2021","unstructured":"Batkai, S. et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur. Heart J. 42, 192\u2013201 (2021).","journal-title":"Eur. Heart J."},{"key":"2112_CR642","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel, J. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 42, 178\u2013188 (2021).","journal-title":"Eur. Heart J."},{"key":"2112_CR643","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","volume":"183","author":"AG Seto","year":"2018","unstructured":"Seto, A. G. et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br. J. Haematol. 183, 428\u2013444 (2018).","journal-title":"Br. J. Haematol."},{"key":"2112_CR644","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","volume":"27","author":"E Anastasiadou","year":"2021","unstructured":"Anastasiadou, E. et al. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin. Cancer Res. 27, 1139\u20131149 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2112_CR645","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.3390\/molecules26216530","volume":"26","author":"CP Tan","year":"2021","unstructured":"Tan, C. P. et al. RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription. Molecules 26, 6530 (2021).","journal-title":"Molecules"},{"key":"2112_CR646","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2012.0354","volume":"22","author":"M Kosaka","year":"2012","unstructured":"Kosaka, M., Kang, M. R., Yang, G. & Li, L. C. Targeted p21WAF1\/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells. Nucleic Acid Ther. 22, 335\u2013343 (2012).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR647","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.5","volume":"1","author":"RF Place","year":"2012","unstructured":"Place, R. F. et al. Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression. Mol. Ther. Nucleic Acids 1, e15 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR648","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-632","volume":"10","author":"J Wei","year":"2010","unstructured":"Wei, J. et al. p21WAF1\/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell. BMC Cancer 10, 632 (2010).","journal-title":"BMC Cancer"},{"key":"2112_CR649","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/aps.2011.28","volume":"32","author":"ZM Wu","year":"2011","unstructured":"Wu, Z. M. et al. Anti-cancer effects of p21WAF1\/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines. Acta Pharm. Sin. 32, 939\u2013946 (2011).","journal-title":"Acta Pharm. Sin."},{"key":"2112_CR650","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/030089161209800620","volume":"98","author":"Z Zhang","year":"2012","unstructured":"Zhang, Z. et al. Up-regulation of p21WAF1\/CIP1 by small activating RNA inhibits the in vitro and in vivo growth of pancreatic cancer cells. Tumori 98, 804\u2013811 (2012).","journal-title":"Tumori"},{"key":"2112_CR651","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2008.02.014","volume":"265","author":"K Yang","year":"2008","unstructured":"Yang, K. et al. Up-regulation of p21WAF1\/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Cancer Lett. 265, 206\u2013214 (2008).","journal-title":"Cancer Lett."},{"key":"2112_CR652","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/0008-5472.CAN-12-1871","volume":"72","author":"MR Kang","year":"2012","unstructured":"Kang, M. R. et al. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res. 72, 5069\u20135079 (2012).","journal-title":"Cancer Res."},{"key":"2112_CR653","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/thx.40.11.866","volume":"40","author":"JR Gosney","year":"1985","unstructured":"Gosney, J. R., Sissons, M. C. & O\u2019Malley, J. A. Quantitative study of endocrine cells immunoreactive for calcitonin in the normal adult human lung. Thorax 40, 866\u2013869, (1985).","journal-title":"Thorax"},{"key":"2112_CR654","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11427-022-2171-2","volume":"66","author":"C Zhang","year":"2023","unstructured":"Zhang, C. & Zhang, B. RNA therapeutics: updates and future potential. Sci. China Life Sci. 66, 12\u201330 (2023).","journal-title":"Sci. China Life Sci."},{"key":"2112_CR655","doi-asserted-by":"publisher","first-page":"9168","DOI":"10.3390\/ijms22179168","volume":"22","author":"KW Huang","year":"2021","unstructured":"Huang, K. W. et al. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models. Int. J. Mol Sci. 22, 9168 (2021).","journal-title":"Int. J. Mol Sci."},{"key":"2112_CR656","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ymthe.2019.02.018","volume":"27","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol. Ther. 27, 999\u20131016 (2019).","journal-title":"Mol. Ther."},{"key":"2112_CR657","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/sj.leu.2403614","volume":"19","author":"H Leroy","year":"2005","unstructured":"Leroy, H. et al. CEBPA point mutations in hematological malignancies. Leukemia 19, 329\u2013334 (2005).","journal-title":"Leukemia"},{"key":"2112_CR658","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/onc.2017.151","volume":"36","author":"AR Louren\u00e7o","year":"2017","unstructured":"Louren\u00e7o, A. R. & Coffer, P. J. A tumor suppressor role for C\/EBP\u03b1 in solid tumors: more than fat and blood. Oncogene 36, 5221\u20135230 (2017).","journal-title":"Oncogene"},{"key":"2112_CR659","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/hep.26669","volume":"59","author":"V Reebye","year":"2014","unstructured":"Reebye, V. et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 59, 216\u2013227 (2014).","journal-title":"Hepatology"},{"key":"2112_CR660","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/mt.2016.142","volume":"24","author":"Y Li","year":"2016","unstructured":"Li, Y., Fung, J. & Lin, F. Local Inhibition of Complement Improves Mesenchymal Stem Cell Viability and Function After Administration. Mol. Ther. 24, 1665\u20131674 (2016).","journal-title":"Mol. Ther."},{"key":"2112_CR661","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.omtn.2019.08.017","volume":"18","author":"S Yoon","year":"2019","unstructured":"Yoon, S. et al. Targeted Delivery of C\/EBP\u03b1-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC. Mol. Ther. Nucleic Acids 18, 142\u2013154 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2112_CR662","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1038\/s41388-018-0126-2","volume":"37","author":"V Reebye","year":"2018","unstructured":"Reebye, V. et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene 37, 3216\u20133228 (2018).","journal-title":"Oncogene"},{"key":"2112_CR663","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","volume":"26","author":"D Sarker","year":"2020","unstructured":"Sarker, D. et al. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C\/EBP-\u03b1, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin. Cancer Res. 26, 3936\u20133946 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2112_CR664","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpha.2020.08.001","volume":"11","author":"S Bian","year":"2021","unstructured":"Bian, S., Zhu, B., Rong, G. & Sawan, M. Towards wearable and implantable continuous drug monitoring: A review. J. Pharm. Anal. 11, 1\u201314 (2021).","journal-title":"J. Pharm. Anal."},{"key":"2112_CR665","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1109\/TBME.2010.2076811","volume":"58","author":"JO Hahn","year":"2011","unstructured":"Hahn, J. O., Dumont, G. A. & Ansermino, J. M. Closed-loop anesthetic drug concentration estimation using clinical-effect feedback. IEEE Trans. Biomed. Eng. 58, 3\u20136 (2011).","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"2112_CR666","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euroneuro.2024.02.009","volume":"83","author":"S Zaragoza Domingo","year":"2024","unstructured":"Zaragoza Domingo, S. et al. Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical Trials. Eur. Neuropsychopharmacol. 83, 32\u201342 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2112_CR667","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"2112_CR668","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jgg.2021.03.007","volume":"48","author":"F Feng","year":"2021","unstructured":"Feng, F. et al. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. J. Genet Genomics 48, 540\u2013551 (2021).","journal-title":"J. Genet Genomics"},{"key":"2112_CR669","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","volume":"20","author":"D Adams","year":"2021","unstructured":"Adams, D. et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 20, 49\u201359 (2021).","journal-title":"Lancet Neurol."},{"key":"2112_CR670","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia, P. et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur. J. Heart Fail 26, 397\u2013410 (2024).","journal-title":"Eur. J. Heart Fail"},{"key":"2112_CR671","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ehf2.13154","volume":"8","author":"NJ Viney","year":"2021","unstructured":"Viney, N. J. et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail 8, 652\u2013661 (2021).","journal-title":"ESC Heart Fail"},{"key":"2112_CR672","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T. et al. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. Jama 330, 1448\u20131458 (2023).","journal-title":"Jama"},{"key":"2112_CR673","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.tips.2022.01.006","volume":"43","author":"DJ Foster","year":"2022","unstructured":"Foster, D. J. Muscarinic receptors: from clinic to bench to clinic. Trends Pharm. Sci. 43, 461\u2013463 (2022).","journal-title":"Trends Pharm. Sci."},{"key":"2112_CR674","doi-asserted-by":"publisher","first-page":"109997","DOI":"10.1016\/j.biopha.2020.109997","volume":"125","author":"X Liang","year":"2020","unstructured":"Liang, X., Li, D., Leng, S. & Zhu, X. RNA-based pharmacotherapy for tumors: From bench to clinic and back. Biomed. Pharmacother. 125, 109997 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2112_CR675","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10198-018-0995-x","volume":"19","author":"L Garattini","year":"2018","unstructured":"Garattini, L. & Padula, A. Pharmaceutical pricing conundrum: time to get rid of it? Eur. J. Health Econ. 19, 1035\u20131038 (2018).","journal-title":"Eur. J. Health Econ."},{"key":"2112_CR676","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-020-2117-z","volume":"580","author":"C Gorgulla","year":"2020","unstructured":"Gorgulla, C. et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580, 663\u2013668 (2020).","journal-title":"Nature"},{"key":"2112_CR677","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nrd1347","volume":"3","author":"MD Rawlins","year":"2004","unstructured":"Rawlins, M. D. Cutting the cost of drug development? Nat. Rev. Drug Discov. 3, 360\u2013364 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR678","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/nat.2021.0071","volume":"32","author":"PH Hagedorn","year":"2022","unstructured":"Hagedorn, P. H. et al. Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features. Nucleic Acid Ther. 32, 151\u2013162 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"2112_CR679","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1128\/CMR.16.4.637-646.2003","volume":"16","author":"S Janssens","year":"2003","unstructured":"Janssens, S. & Beyaert, R. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol Rev. 16, 637\u2013646, (2003).","journal-title":"Clin. Microbiol Rev."},{"key":"2112_CR680","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1073\/pnas.0631696100","volume":"100","author":"J Lee","year":"2003","unstructured":"Lee, J. et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl Acad. Sci. USA 100, 6646\u20136651 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR681","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526\u20131529 (2004).","journal-title":"Science"},{"key":"2112_CR682","doi-asserted-by":"publisher","first-page":"8107","DOI":"10.1093\/nar\/gkac618","volume":"50","author":"AJ Pollak","year":"2022","unstructured":"Pollak, A. J. et al. Insights into innate immune activation via PS-ASO-protein-TLR9 interactions. Nucleic Acids Res. 50, 8107\u20138126 (2022).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR683","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","volume":"27","author":"TH Brannagan","year":"2020","unstructured":"Brannagan, T. H. et al. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur. J. Neurol. 27, 1374\u20131381 (2020).","journal-title":"Eur. J. Neurol."},{"key":"2112_CR684","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3324\/haematol.2020.260059","volume":"107","author":"MHL Slingsby","year":"2022","unstructured":"Slingsby, M. H. L. et al. Sequence-specific 2\u2019-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates. Haematologica 107, 519\u2013531 (2022).","journal-title":"Haematologica"},{"key":"2112_CR685","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01326-8","volume":"20","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Mechanistic study of silica nanoparticles on the size-dependent retinal toxicity in vitro and in vivo. J. Nanobiotechnol. 20, 146 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"2112_CR686","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","volume":"5","author":"MP Lokugamage","year":"2021","unstructured":"Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059\u20131068 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2112_CR687","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41587-023-01679-x","volume":"41","author":"B Li","year":"2023","unstructured":"Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410\u20131415 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR688","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31993-y","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Multi-step screening of DNA\/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nat. Commun. 13, 4282 (2022).","journal-title":"Nat. Commun."},{"key":"2112_CR689","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306129120","volume":"120","author":"A Olshefsky","year":"2023","unstructured":"Olshefsky, A. et al. In vivo selection of synthetic nucleocapsids for tissue targeting. Proc. Natl Acad. Sci. USA 120, e2306129120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR690","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/imm.12838","volume":"153","author":"C Parola","year":"2018","unstructured":"Parola, C., Neumeier, D. & Reddy, S. T. Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology 153, 31\u201341 (2018).","journal-title":"Immunology"},{"key":"2112_CR691","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","volume":"73","author":"E Kon","year":"2022","unstructured":"Kon, E., Elia, U. & Peer, D. Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr. Opin. Biotechnol. 73, 329\u2013336 (2022).","journal-title":"Curr. Opin. Biotechnol."},{"key":"2112_CR692","doi-asserted-by":"publisher","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","volume":"115","author":"CD Sago","year":"2018","unstructured":"Sago, C. D. et al. High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. Proc. Natl Acad. Sci. USA 115, E9944\u2013e9952 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2112_CR693","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201906128","volume":"32","author":"S Ramishetti","year":"2020","unstructured":"Ramishetti, S. et al. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv. Mater. 32, e1906128 (2020).","journal-title":"Adv. Mater."},{"key":"2112_CR694","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley, M. M. et al. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 20, 1578\u20131589 (2020).","journal-title":"Nano Lett."},{"key":"2112_CR695","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41551-019-0351-1","volume":"3","author":"G Yamankurt","year":"2019","unstructured":"Yamankurt, G. et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat. Biomed. Eng. 3, 318\u2013327 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"2112_CR696","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41563-017-0007-z","volume":"17","author":"Y Shamay","year":"2018","unstructured":"Shamay, Y. et al. Quantitative self-assembly prediction yields targeted nanomedicines. Nat. Mater. 17, 361\u2013368 (2018).","journal-title":"Nat. Mater."},{"key":"2112_CR697","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41565-023-01323-4","volume":"18","author":"M Zhu","year":"2023","unstructured":"Zhu, M. et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat. Nanotechnol. 18, 657\u2013666 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"2112_CR698","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.actbio.2022.09.072","volume":"154","author":"D Gong","year":"2022","unstructured":"Gong, D. et al. Machine learning guided structure function predictions enable in silico nanoparticle screening for polymeric gene delivery. Acta Biomater. 154, 349\u2013358 (2022).","journal-title":"Acta Biomater."},{"key":"2112_CR699","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41551-022-00991-2","volume":"7","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences. Nat. Biomed. Eng. 7, 797\u2013810 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2112_CR700","doi-asserted-by":"publisher","first-page":"eabm5551","DOI":"10.1126\/science.abm5551","volume":"377","author":"N Boehnke","year":"2022","unstructured":"Boehnke, N. et al. Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery. Science 377, eabm5551 (2022).","journal-title":"Science"},{"key":"2112_CR701","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/acscentsci.2c00382","volume":"8","author":"CM Heil","year":"2022","unstructured":"Heil, C. M., Patil, A., Dhinojwala, A. & Jayaraman, A. Computational Reverse-Engineering Analysis for Scattering Experiments (CREASE) with Machine Learning Enhancement to Determine Structure of Nanoparticle Mixtures and Solutions. ACS Cent. Sci. 8, 996\u20131007 (2022).","journal-title":"ACS Cent. Sci."},{"key":"2112_CR702","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters, O. J., McKee, M. & Luyten, J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. Jama 323, 844\u2013853 (2020).","journal-title":"Jama"},{"key":"2112_CR703","doi-asserted-by":"publisher","first-page":"106894","DOI":"10.1016\/j.bioorg.2023.106894","volume":"141","author":"Q Lv","year":"2023","unstructured":"Lv, Q., Zhou, F., Liu, X. & Zhi, L. Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work? Bioorg. Chem. 141, 106894 (2023).","journal-title":"Bioorg. Chem."},{"key":"2112_CR704","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00000658-198709000-00007","volume":"206","author":"RJ Fitzgibbons Jr","year":"1987","unstructured":"Fitzgibbons, R. J. Jr et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II). Ann. Surg. 206, 289\u2013295 (1987).","journal-title":"Ann. Surg."},{"key":"2112_CR705","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jbi.2012.02.005","volume":"45","author":"M Mysara","year":"2012","unstructured":"Mysara, M., Elhefnawi, M. & Garibaldi, J. M. MysiRNA: improving siRNA efficacy prediction using a machine-learning model combining multi-tools and whole stacking energy (\u0394G). J. Biomed. Inf. 45, 528\u2013534, (2012).","journal-title":"J. Biomed. Inf."},{"key":"2112_CR706","doi-asserted-by":"publisher","first-page":"W193","DOI":"10.1093\/nar\/gkab442","volume":"49","author":"S Chiba","year":"2021","unstructured":"Chiba, S. et al. eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping. Nucleic Acids Res. 49, W193\u2013w198 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR707","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2014.05.030","volume":"193","author":"MK Joo","year":"2014","unstructured":"Joo, M. K., Yhee, J. Y., Kim, S. H. & Kim, K. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J. Control Release 193, 113\u2013121, (2014).","journal-title":"J. Control Release"},{"key":"2112_CR708","doi-asserted-by":"publisher","first-page":"130638","DOI":"10.1016\/j.ijbiomac.2024.130638","volume":"264","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Cm-siRPred: Predicting chemically modified siRNA efficiency based on multi-view learning strategy. Int J. Biol. Macromol. 264, 130638 (2024).","journal-title":"Int J. Biol. Macromol."},{"key":"2112_CR709","doi-asserted-by":"publisher","first-page":"110815","DOI":"10.1016\/j.ygeno.2024.110815","volume":"116","author":"DD Martinelli","year":"2024","unstructured":"Martinelli, D. D. From sequences to therapeutics: Using machine learning to predict chemically modified siRNA activity. Genomics 116, 110815 (2024).","journal-title":"Genomics"},{"key":"2112_CR710","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).","journal-title":"Nat. Commun."},{"key":"2112_CR711","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.adh1114","volume":"381","author":"F Wong","year":"2023","unstructured":"Wong, F., de la Fuente-Nunez, C. & Collins, J. J. Leveraging artificial intelligence in the fight against infectious diseases. Science 381, 164\u2013170 (2023).","journal-title":"Science"},{"key":"2112_CR712","doi-asserted-by":"publisher","first-page":"113922","DOI":"10.1016\/j.addr.2021.113922","volume":"178","author":"S He","year":"2021","unstructured":"He, S., Leanse, L. G. & Feng, Y. Artificial intelligence and machine learning assisted drug delivery for effective treatment of infectious diseases. Adv. Drug Deliv. Rev. 178, 113922 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR713","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1021\/acs.accounts.1c00621","volume":"55","author":"SM Castillo-Hair","year":"2022","unstructured":"Castillo-Hair, S. M. & Seelig, G. Machine Learning for Designing Next-Generation mRNA Therapeutics. Acc. Chem. Res 55, 24\u201334 (2022).","journal-title":"Acc. Chem. Res"},{"key":"2112_CR714","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.drudis.2021.09.006","volume":"27","author":"P Moingeon","year":"2022","unstructured":"Moingeon, P., Kuenemann, M. & Guedj, M. Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. Drug Discov. Today 27, 215\u2013222 (2022).","journal-title":"Drug Discov. Today"},{"key":"2112_CR715","doi-asserted-by":"publisher","first-page":"115073","DOI":"10.1016\/j.addr.2023.115073","volume":"201","author":"J Won Lee","year":"2023","unstructured":"Won Lee, J. et al. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges. Adv. Drug Deliv. Rev. 201, 115073 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR716","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","volume":"2","author":"BB Mendes","year":"2022","unstructured":"Mendes, B. B. et al. Nanodelivery of nucleic acids. Nat. Rev. Methods Primers. 2, 24 (2022).","journal-title":"Nat. Rev. Methods Primers."},{"key":"2112_CR717","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong, Y., Siegwart, D. J. & Anderson, D. G. Strategies, design, and chemistry in siRNA delivery systems. Adv. Drug Deliv. Rev. 144, 133\u2013147 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2112_CR718","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jconrel.2016.05.063","volume":"235","author":"V Rengaswamy","year":"2016","unstructured":"Rengaswamy, V., Zimmer, D., S\u00fcss, R. & R\u00f6ssler, J. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy. J. Control Release 235, 319\u2013327 (2016).","journal-title":"J. Control Release"},{"key":"2112_CR719","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341\u2013345 (2011).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR720","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.biomaterials.2012.09.047","volume":"34","author":"JY Kim","year":"2013","unstructured":"Kim, J. Y., Choi, W. I., Kim, Y. H. & Tae, G. Brain-targeted delivery of protein using chitosan- and RVG peptide-conjugated, pluronic-based nano-carrier. Biomaterials 34, 1170\u20131178, (2013).","journal-title":"Biomaterials"},{"key":"2112_CR721","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.biomaterials.2011.03.047","volume":"32","author":"DW Hwang","year":"2011","unstructured":"Hwang, D. W. et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32, 4968\u20134975 (2011).","journal-title":"Biomaterials"},{"key":"2112_CR722","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jconrel.2024.04.006","volume":"369","author":"L Tang","year":"2024","unstructured":"Tang, L. et al. A blood-brain barrier- and blood-brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy. J. Control Release 369, 642\u2013657 (2024).","journal-title":"J. Control Release"},{"key":"2112_CR723","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1039\/D2CS00998F","volume":"52","author":"L Fu","year":"2023","unstructured":"Fu, L. et al. Passive\u2019 nanoparticles for organ-selective systemic delivery: design, mechanism and perspective. Chem. Soc. Rev. 52, 7579\u20137601 (2023).","journal-title":"Chem. Soc. Rev."},{"key":"2112_CR724","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"2112_CR725","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2013.05.015","volume":"170","author":"ME Bonnet","year":"2013","unstructured":"Bonnet, M. E. et al. Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J. Control Release 170, 183\u2013190 (2013).","journal-title":"J. Control Release"},{"key":"2112_CR726","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jconrel.2018.04.003","volume":"279","author":"T Okuda","year":"2018","unstructured":"Okuda, T. et al. Development of spray-freeze-dried siRNA\/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity. J. Control Release 279, 99\u2013113 (2018).","journal-title":"J. Control Release"},{"key":"2112_CR727","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2023.09.038","volume":"363","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Cellular organelles as drug carriers for disease treatment. J. Control Release 363, 114\u2013135 (2023).","journal-title":"J. Control Release"},{"key":"2112_CR728","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang, Y., Duan, L., Lu, J. & Xia, J. Engineering exosomes for targeted drug delivery. Theranostics 11, 3183\u20133195 (2021).","journal-title":"Theranostics"},{"key":"2112_CR729","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41580-020-0210-7","volume":"21","author":"M Giacomello","year":"2020","unstructured":"Giacomello, M., Pyakurel, A., Glytsou, C. & Scorrano, L. The cell biology of mitochondrial membrane dynamics. Nat. Rev. Mol. Cell Biol. 21, 204\u2013224 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2112_CR730","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1021\/acsnano.9b10033","volume":"14","author":"BS Joshi","year":"2020","unstructured":"Joshi, B. S., de Beer, M. A., Giepmans, B. N. G. & Zuhorn, I. S. Endocytosis of Extracellular Vesicles and Release of Their Cargo from Endosomes. ACS Nano 14, 4444\u20134455 (2020).","journal-title":"ACS Nano"},{"key":"2112_CR731","doi-asserted-by":"crossref","unstructured":"Chen, W., Huang, T., Shi, K., Chu, B., & Qian, Z. Chemotaxis-based self-accumulation of surface-engineered mitochondria for cancer therapeutic improvement. Nano Today. Nano Today. 35, (2020).","DOI":"10.1016\/j.nantod.2020.100966"},{"key":"2112_CR732","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6981","volume":"13","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci. Transl. Med. 13, eabb6981 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2112_CR733","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216093","volume":"558","author":"R Raguraman","year":"2023","unstructured":"Raguraman, R. et al. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 558, 216093 (2023).","journal-title":"Cancer Lett."},{"key":"2112_CR734","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/molecules25122866","volume":"25","author":"A Wahane","year":"2020","unstructured":"Wahane, A. et al. Role of Lipid-Based and Polymer-Based Non-Viral Vectors in Nucleic Acid Deliveryfor Next-Generation Gene Therapy. Molecules 25, 2866 (2020).","journal-title":"Molecules"},{"key":"2112_CR735","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1146\/annurev-pharmtox-032320-110338","volume":"61","author":"W Yang","year":"2021","unstructured":"Yang, W. et al. Nanoparticle Toxicology. Annu Rev. Pharm. Toxicol. 61, 269\u2013289 (2021).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"2112_CR736","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1021\/acs.nanolett.0c00432","volume":"20","author":"JA Shatkin","year":"2020","unstructured":"Shatkin, J. A. The Future in Nanosafety. Nano Lett. 20, 1479\u20131480 (2020).","journal-title":"Nano Lett."},{"key":"2112_CR737","doi-asserted-by":"publisher","first-page":"10644","DOI":"10.1021\/acsnano.7b07120","volume":"11","author":"S Wilhelm","year":"2017","unstructured":"Wilhelm, S. Perspectives for Upconverting Nanoparticles. ACS Nano 11, 10644\u201310653 (2017).","journal-title":"ACS Nano"},{"key":"2112_CR738","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1021\/acs.accounts.9b00053","volume":"52","author":"JT Buchman","year":"2019","unstructured":"Buchman, J. T., Hudson-Smith, N. V., Landy, K. M. & Haynes, C. L. Understanding Nanoparticle Toxicity Mechanisms To Inform Redesign Strategies To Reduce Environmental Impact. Acc. Chem. Res 52, 1632\u20131642 (2019).","journal-title":"Acc. Chem. Res"},{"key":"2112_CR739","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.biopha.2018.04.126","volume":"103","author":"A Eftekhari","year":"2018","unstructured":"Eftekhari, A. et al. The promising future of nano-antioxidant therapy against environmental pollutants induced-toxicities. Biomed. Pharmacother. 103, 1018\u20131027 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2112_CR740","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1039\/D2MH01512A","volume":"10","author":"X Jing","year":"2023","unstructured":"Jing, X. et al. Surface engineering of colloidal nanoparticles. Mater. Horiz. 10, 1185\u20131209 (2023).","journal-title":"Mater. Horiz."},{"key":"2112_CR741","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1021\/ja910846q","volume":"132","author":"YS Lin","year":"2010","unstructured":"Lin, Y. S. & Haynes, C. L. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J. Am. Chem. Soc. 132, 4834\u20134842, (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR742","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/acsami.6b14450","volume":"9","author":"L Rao","year":"2017","unstructured":"Rao, L. et al. Erythrocyte Membrane-Coated Upconversion Nanoparticles with Minimal Protein Adsorption for Enhanced Tumor Imaging. ACS Appl. Mater. Interf. 9, 2159\u20132168 (2017).","journal-title":"ACS Appl. Mater. Interf."},{"key":"2112_CR743","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","volume":"37","author":"Y Weng","year":"2019","unstructured":"Weng, Y. et al. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. 37, 801\u2013825 (2019).","journal-title":"Biotechnol. Adv."},{"key":"2112_CR744","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds, A. et al. Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326\u2013330 (2004).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR745","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cgt.2016.4","volume":"23","author":"E Fakhr","year":"2016","unstructured":"Fakhr, E., Zare, F. & Teimoori-Toolabi, L. Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 23, 73\u201382 (2016).","journal-title":"Cancer Gene Ther."},{"key":"2112_CR746","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/nar\/gkh247","volume":"32","author":"K Ui-Tei","year":"2004","unstructured":"Ui-Tei, K. et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32, 936\u2013948 (2004).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR747","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","volume":"19","author":"BD Boros","year":"2022","unstructured":"Boros, B. D., Schoch, K. M., Kreple, C. J. & Miller, T. M. Antisense Oligonucleotides for the Study and Treatment of ALS. Neurotherapeutics 19, 1145\u20131158 (2022).","journal-title":"Neurotherapeutics"},{"key":"2112_CR748","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito, T. et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat. Neurosci. 17, 661\u2013663 (2014).","journal-title":"Nat. Neurosci."},{"key":"2112_CR749","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1007\/s12035-021-02385-y","volume":"58","author":"Q Xia","year":"2021","unstructured":"Xia, Q. et al. The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer\u2019s Disease. Mol. Neurobiol. 58, 4038\u20134050 (2021).","journal-title":"Mol. Neurobiol."},{"key":"2112_CR750","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1021\/acs.accounts.8b00650","volume":"52","author":"M Egli","year":"2019","unstructured":"Egli, M. & Manoharan, M. Re-Engineering RNA Molecules into Therapeutic Agents. Acc. Chem. Res. 52, 1036\u20131047 (2019).","journal-title":"Acc. Chem. Res."},{"key":"2112_CR751","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238\u2013248 (2017).","journal-title":"Nat. Biotechnol."},{"key":"2112_CR752","doi-asserted-by":"publisher","first-page":"14517","DOI":"10.1021\/jacs.2c01679","volume":"144","author":"DC Guenther","year":"2022","unstructured":"Guenther, D. C. et al. Role of a \u201cMagic\u201d Methyl: 2\u2019-Deoxy-2\u2019-\u03b1-F-2\u2019-\u03b2-C-methyl Pyrimidine Nucleotides Modulate RNA Interference Activity through Synergy with 5\u2019-Phosphate Mimics and Mitigation of Off-Target Effects. J. Am. Chem. Soc. 144, 14517\u201314534 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR753","doi-asserted-by":"publisher","first-page":"W104","DOI":"10.1093\/nar\/gkn250","volume":"36","author":"ZJ Lu","year":"2008","unstructured":"Lu, Z. J. & Mathews, D. H. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res. 36, W104\u2013W108 (2008).","journal-title":"Nucleic Acids Res."},{"key":"2112_CR754","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s44258-024-00019-1","volume":"2","author":"B Liu","year":"2024","unstructured":"Liu, B. et al. AttSiOff: a self-attention-based approach on siRNA design with inhibition and off-target effect prediction. Med-X 2, 5 (2024).","journal-title":"Med-X"},{"key":"2112_CR755","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang, Q. & Khvorova, A. RNAi-based drug design: considerations and future directions. Nat. Rev. Drug Discov. 23, 341\u2013364 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2112_CR756","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41557-021-00645-x","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang, Y., Nguyen, K., Spitale, R. C. & Chaput, J. C. A biologically stable DNAzyme that efficiently silences gene expression in cells. Nat. Chem. 13, 319\u2013326 (2021).","journal-title":"Nat. Chem."},{"key":"2112_CR757","doi-asserted-by":"publisher","first-page":"19691","DOI":"10.1021\/jacs.3c04744","volume":"145","author":"S Matsuda","year":"2023","unstructured":"Matsuda, S. et al. Shorter Is Better: The \u03b1-(l)-Threofuranosyl Nucleic Acid Modification Improves Stability, Potency, Safety, and Ago2 Binding and Mitigates Off-Target Effects of Small Interfering RNAs. J. Am. Chem. Soc. 145, 19691\u201319706 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR758","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1021\/jacs.3c14626","volume":"146","author":"H Depmeier","year":"2024","unstructured":"Depmeier, H. & Kath-Schorr, S. Expanding the Horizon of the Xeno Nucleic Acid Space: Threose Nucleic Acids with Increased Information Storage. J. Am. Chem. Soc. 146, 7743\u20137751 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"2112_CR759","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202107820","volume":"34","author":"T Zhang","year":"2022","unstructured":"Zhang, T., Tian, T. & Lin, Y. Functionalizing Framework Nucleic-Acid-Based Nanostructures for Biomedical Application. Adv. Mater. 34, e2107820 (2022).","journal-title":"Adv. Mater."},{"key":"2112_CR760","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. Transcutaneous Immunotherapy for RNAi: A Cascade-Responsive Decomposable Nanocomplex Based on Polyphenol-Mediated Framework Nucleic Acid in Psoriasis. Adv. Sci. (Weinh.) 10, e2303706 (2023).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2112_CR761","doi-asserted-by":"publisher","first-page":"56483","DOI":"10.1021\/acsami.2c15086","volume":"14","author":"PMD Moreno","year":"2022","unstructured":"Moreno, P. M. D., Cortinhas, J., Martins, A. S. & P\u00eago, A. P. Engineering a Novel Self-Assembled Multi-siRNA Nanocaged Architecture with Controlled Enzyme-Mediated siRNA Release. ACS Appl Mater. Interfaces 14, 56483\u201356497 (2022).","journal-title":"ACS Appl Mater. Interfaces"},{"key":"2112_CR762","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1128\/AAC.02823-14","volume":"58","author":"X Wu","year":"2014","unstructured":"Wu, X. et al. In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method. Antimicrob. Agents Chemother. 58, 5342\u20135349 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2112_CR763","doi-asserted-by":"publisher","first-page":"e00368","DOI":"10.1128\/AAC.00368-18","volume":"62","author":"R Zhang","year":"2018","unstructured":"Zhang, R. et al. Novel Self-Assembled Micelles Based on Cholesterol-Modified Antimicrobial Peptide (DP7) for Safe and Effective Systemic Administration in Animal Models of Bacterial Infection. Antimicrob. Agents Chemother. 62, e00368\u201318 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2112_CR764","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0014-5793(97)01123-X","volume":"415","author":"J Oehlke","year":"1997","unstructured":"Oehlke, J. et al. Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide. FEBS Lett. 415, 196\u2013199 (1997).","journal-title":"FEBS Lett."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02112-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02112-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T20:02:26Z","timestamp":1741550546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02112-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":764,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2112"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02112-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}